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Metal ions can have considerable affinities for proteins, and give rise to 
geometric constraints that are often taken advantage of in protein-protein interactions. 
The coordination shell of metal ions can be filled by atoms provided by two different 
proteins, resulting in a high affinity protein complex. Surprisingly, this highly 
efficient binding strategy is rarely observed in immunoglobulins, despite the great 
number of known antibody structures determined in complex with their protein 
antigens.  
 The murine monoclonal antibody HPC-4, directed against the activation 
region of the human anticoagulant zymogen protein C (PC), is one of the few 
immunoglobulins known to display calcium-dependent antigen binding. Unlike the 
more common class of antibodies that merely recognize a calcium-bound 
conformation of their antigen, HPC-4 interacts directly with calcium in the high 
affinity PC-HPC-4 complex.  
 To provide a structural understanding of HPC-4 function and of the particular 
antibody class to which it belongs, we have solved the X-ray crystal structure of the 
HPC-4 Fab fragment in ternary complex with its epitope peptide in the presence of 
calcium at a resolution of 2.3Å. Within the crystal, the antigen-binding region is 
undistorted by crystalline lattice contacts. All complementarity-determining regions 
and the peptide antigen have well-defined electron density.  
 The structure reveals a mode of calcium binding which underlies a novel 
mechanism of metal aided antigen recognition. The ion is located at the antibody-
antigen interface, where it functions both as an electrostatic bridge and as a 
conformational effector of the antibody. The antigen is further stabilized by an 
extensive and diverse array of interactions spanning a large surface area of contact. 
Our results provide a structural explanation for many of the observed characteristics 
of HPC-4, the first member of a unique class of calcium binding antibodies. As such, 
it represents a significant contribution to the study of interfacial metals and the 
structural biology of antibodies. 
ABSTRACT
11.1. Hemostasis 
1.1.1. General background
Blood hemostasis results from 
the combined actions of platelet 
activation, coagulation and fibrinolysis. 
The constantly regulated balance 
between clot formation and 
degradation required to maintain 
proper blood circulation is mediated 
through a network of interactions between these complementary pathways. The 
plasma protease activated protein C (aPC) is an important member of this system, 
illustrated by the fact that genetic defects in the protein C gene are associated with 
increased risks for venous thrombosis(1). aPC is produced by an ensemble of 
activation reactions called the protein C pathway(2,3)(fig. 1) and functions in both 
coagulation and inflammation(2). The present project is primarily focused on its role 
in preventing the propagation of blood clotting away from a wound site. Indeed, very 
high concentrations of the procoagulant precursors prothrombin and fibrinogen are 
necessary to ensure a rapid sealing of any wound and prevent fatal blood losses. An 
exquisitely organized ensemble of interacting regulatory agents is dedicated to 
maintain the overall hemostatic balance over a broad range of accidental 
perturbations.  
1. BACKGROUND
Figure 1: protein C activation and function. PC, 
aPC: protein C, activated protein C. IXa: 
activated factor IX. X, Xa: factor X, activated 
factor X. II: prothrombin. 
21.1.2. The coagulation cascade and the protein C anticoagulant pathway
Thrombin is at the endpoint of a series of proteolytic activations defined as the 
coagulation cascade that is initiated at a site of vascular injury upon exposure of 
blood to tissue factor within the sub-endothelial tissues. The functional unit of this 
amplifying sequence is a complex between an obligatory cofactor and a serine 
protease of the trypsin class. The binding of an enzyme (factor IXa in the example 
shown in fig. 1) to the cofactor (factor VIIIa) enables the specific substrate cleavage 
of a downstream serine protease precursor (zymogen, factor X in fig. 1), which in 
turn activates a different procoagulant zymogen (factor II) in a cofactor-dependent 
(factor Va) fashion. Because blood coagulation operates at the level of mature 
circulating proteins, it mostly depends on the concentrations and chemical rates of the 
procoagulant reactions, and consequently may be very rapid. This benefit is however 
only obtained by having high levels of circulating procoagulant precursors in the 
normal situation. In this condition, any uncontrolled procoagulant signal can 
potentially spread to lethal levels rapidly. The regulatory mechanism of the cascade, 
triggered simultaneously with the formation of the clot, is the anticoagulant protein C 
pathway. Its main function is the proteolytic inactivation of two cofactors (factors Va 
and VIIIa) required for the final amplification steps of the procoagulant pathway(2-4).
The central reaction of this regulatory pathway is the activation of protein C, 
catalyzed by the complex thrombin-thrombomodulin (T-TM)(5) in a process assisted 
by the endothelial protein C receptor, EPCR(6,7). Recruitment of the major 
anticoagulant enzyme thrombin as the initiator of the anticoagulant pathway is an 
elegant solution to ensure that any procoagulant event inherently also generates the 
3enzymatic activities required to stop itself. This process is sometimes referred to as 
autodownregulation(8), or negative feedback(9). Two main mechanisms are available 
to counteract coagulation. At later stages (hours to days after injury), simultaneously 
with wound healing, 
the clots are degraded 
by fibrinolysis, which 
can be used as a 
therapeutic 
treatment(10) as 
extensively reviewed 
elsewhere(8).
Protein C, the substrate of the T-TM complex, is a plasma serine protease of 
the trypsin class synthesized in the liver(11). It is initially secreted as a single 
polypeptide, but the removal of an internal dipeptide (K156R157, see fig. 2) during 
endoplasmic reticular transit results in the formation of a disulfide bonded 
heterodimeric species constituted of a light chain and a heavy chain(12,13). About 20 % 
of plasma protein C circulates as a single chain isoform where the dipeptide is still 
present(12,13). This form has the same reactivity towards the T-TM complex, and 
yields a functionally identical version of the active protease(14). The light chain 
contains a gamma carboxyglutamic acid domain (“Gla domain”), a helical aromatic 
segment, two successive epidermal growth factor-like domains (“EGF domains”) and 
a C-terminal peptide linking to the interchain disulfide(15). The heavy chain is a serine 
protease domain. It contains the canonical catalytic triad of residues (H57, D102, S195)
Figure 2: Sequence of protein C (human) in the activation region. The 
Schechter&Berger numbering is shown atop the sequence. The aPC 
heavy chain numbering is shown below the sequence. The epitope 
peptide used throughout this project is shown. 
4which carry the catalytic activity of the 
enzyme(16). The structure of a Gla 
domainless form of the activated protein C 
was solved at 2.8Å resolution(17) (fig. 3). 
The activation reaction takes place at the 
amino terminus of the heavy chain, where a 
12 residue peptide is removed by cleavage 
of the R12-L13 peptide bond by the T-TM 
complex(3). Structural evidence demonstrates 
that the newly formed amino-terminus then 
folds back in a canonical fashion(18) inside 
the serine protease domain, where it forms a buried ion pair with D194(17). The ensuing 
conformational rearrangement is transmitted to the active site, resulting in a 
catalytically competent enzyme.  
1.1.3. Thrombomodulin influences the properties of thrombin
The binding of thrombin to the endothelial receptor thrombomodulin (TM) 
induces profound changes in the enzyme that enable it to activate the anticoagulant 
protein C while suppressing its procoagulant activities(5). The unique cofactor activity 
of TM resides within a tandem repeat of six epidermal growth factor domains (EGF 
domain). The binding site of thrombin is located in the last 2 EGF-like folds of the 
EGF domain (TM56)(19), but all of the last 3 EGF-like folds (TM456) are required for 
a full cofactor activity(20).
Figure 3: aPC, from pdb code 1AUT. Blue: 
EGF1, red: EGF2, green: protease 
domain. The catalytic triad is visible as 
sticks. The intrachain disulfide is visible as 
yellow sticks.
5Although the role of TM in blocking the procoagulant activities of thrombin is 
well established, the precise mechanism by which it confers to thrombin the novel 
ability to activate protein C remains unclear. The nanomolar affinity of 
thrombomodulin for thrombin certainly outcompetes other procoagulant substrates 
that share the same binding site(21), and several lines of evidence show the presence of 
a protein C binding site on TM4(22-24). This orienting effect is comparable to other 
reactions of the coagulation pathway(25), and was confirmed by the structure of 
thrombin in complex with the TM456 fragment of thrombomodulin(26), in which only 
modest changes were found in the structure of thrombin. In this study, it was 
concluded that the binding event only increases the activation rate by providing a 
binding site for protein C on the activating complex. However, this result must be 
taken with caution and could be an artifact from the stabilizing presence of the 
covalent inhibitor d-Phe-Pro-Arg chloromethyl ketone (PPACK) in the structure(27) or 
related to packing contacts which fill the TM binding site of the apo-thrombin 
structure used for comparison (manuscript in preparation). Furthermore, a growing 
body of evidence shows that the most prominent effect of thrombomodulin is the 
modulation of the catalytic rate of thrombin hydrolysis rather than affinity 
improvement alone. This type of effect(28) suggests that thrombomodulin could be an 
allosteric effector of thrombin. Results obtained by differential scanning 
calorimetry(29), differential susceptibility to proteolysis(30,31), active site-tethered 
fluorescent probes(32), spin-label agents(33), deuterium exchange-mass 
spectrometry(29,34) and site-directed mutational analysis(35,36) all converge to the same 
6hypothetical mechanism in which binding of this cofactor is able to modify the 
conformation of distal sites including the active center of thrombin.   
 The structure of the substrate protein C also plays an important role in the 
activation reaction. This is illustrated by the fact that the conformational changes 
induced by calcium in protein C(14,37) are able to alter its activation rate by either 
thrombin or the thrombin-thrombomodulin complex(3,38,39) (Fig. 4). This effect has 
tentatively been addressed by theoretical modeling approaches(26,40), but important 
discrepancies appear between the proposed 
models. By virtue of its experimental nature, 
our project may provide a more conclusive 
answer about the influence of calcium on the 
activation of protein C by the T-TM 
complex. 
 Overall, the precise molecular mechanism of this modulation appears to be 
that TM provides both a weak binding site for protein C that optimizes its cleavage, 
and an improved catalytic rate through an allosteric effect. The knowledge of the 
conformation of the calcium-bound form of the substrate would improve our 
understanding of the mechanism of thrombomodulin-mediated specificity change of 
thrombin. 
 
Figure 4: Calcium dependency of protein 
C activation. Reproduced from ref. (3). 
71.2. The calcium dependent antibody HPC-4 
 
The monoclonal antibody HPC-4, directed at the activation region of the  
human anticoagulant protease precursor protein C (linear epitope represented in fig. 
2), has the remarkable characteristic of a high magnitude and reversible increase of 
affinity for the antigen only in the presence of calcium(41). Initial biochemical 
characterizations concluded that this unusual characteristic stems from the presence 
of a calcium binding site on the antibody, but its exact nature and the resulting 
mechanism of the calcium dependence of HPC-4 remained under discussion. In 
particular, the coordination of the calcium ion could be fully provided by the 
antibody, resulting in a conformational switch that would trigger the conversion of 
HPC-4 to a high affinity state. Alternatively, the simpler mechanism of strict 
electrostatic bridging likely to occur in the only other structurally solved calcium 
dependent antibody Q-425 could also explain some of the biochemical data for HPC-
4. These two mechanisms are not exclusive and could likely be combined. The 
resulting dual effect of conformational rearrangement of the antibody and 
electrostatic bridging, although unique in the extensively characterized field of 
antibody-antigen interactions, is not without precedent in other systems. 
 The region of protein C recognized by HPC-4 is centered on the peptide bond 
cleaved during the activation reaction by the thrombin-thrombomodulin complex (T-
TM)(41). The activation peptide released during activation is not recognized by HPC-
4, nor is the activated protein C (aPC). The crystal structure of aPC(17) clearly shows 
that the portion of HPC-4 epitope which remains after activation is recruited away 
8from the solvent to provide a buried ion pair essential to the catalytically active 
conformation of the active site triad. Importantly, protein C activation by T-TM only 
occurs when the region of the scissile bond undergoes a conformational change 
induced by the binding of calcium to the calcium binding loop in the protease domain 
of protein C(14,17,39,42). Structural modeling, homology modeling and molecular 
dynamics simulation results suggest that this effect is mediated through direct contact 
between the two regions(17,40). Importantly, the calcium dependence of HPC-4 binding 
was observed even for the small peptide of protein C that spans the scissile bond, thus 
devoid of the structural influence of the calcium-binding loop of the serine protease 
domain.  
 To decipher the effects of calcium on HPC-4 and the resulting increase of 
affinity for even a structurally relaxed antigen, we have solved the X-ray crystal 
structure of an antigen binding fragment (“Fab”) variant of HPC-4 in complex with 
the 9 residues protein C epitope peptide in the presence of calcium. Our results 
provide important insights into the mostly unexplored field of interfacial metal aided 
antigen recognition.  
 
1.3. Structural biology and biochemical aspects of 
antibody-antigen interactions 
 
Antibodies are heterotetramers of 2 heavy and two light chains linked by 
disulfide bonds. Heavy and light chains are built with repetitions of a common all-M
structural domain (the Ig fold) belonging to the immunoglobulin structural 
superfamily, as defined in the SCOP (structural classification of proteins(43)). Heavy 
9chains have 4 Ig folds, while light chains 
only have 2. Heavy chains are bound 
together between the second and third Ig 
domains by several disulfide bonds of 
the hinge region. Each heavy chain is 
bound to a light chain by one disulfide 
bond. There are an additional 12 
intrachain disulfide bonds, one in each 
Ig domain. The first Ig domains of both the heavy and light chains are grouped in the 
tertiary structure, and together form the antigen binding site. The Ig folds 
participating in antigen binding have an additional two strands that are important for 
their function.  
 Antibodies can be fragmented by proteolysis, yielding different fragments 
depending on the place of cleavage. In the case of a cleavage N-terminal to the hinge 
region, two monovalent “Fab” fragments are generated along with the constant 
fragment (“Fc”). In the case of a cleavage C-terminal to the hinge region, the bivalent 
Fab’2 fragment is obtained together with the Fc. These different possibilities are 
presented on figure 5.  
 Antigen specificity arises from the high sequence variability encountered in 
the loops that connect the strands 2-3, 3b-3c and 6-7 (fig. 6). The molecular basis for 
antigen recognition is reasonably well understood, mostly because many high 
resolution crystal structures of antibody fragments in presence or absence of their 
antigen have been solved. First, the structural variability of antibody molecules is 
F(ab’)2
F(ab’)
F(ab)
A
B B
A : cleavage above 
the hinge region
B : cleavage below 
the hinge region
selective 
reduction
Figure 5: Antibody hydrolysis fragmentation 
routes. Dark blue : heavy chains ; light blue: 
light chains. Interchain disulfides are depicted 
as yellow boxes. 
10 
almost exclusively located in hypervariable regions, the rest of the fold being 
essentially identical in structure between different antibodies. Protein-binding 
antibodies share the additional feature of having an antigen binding site resembling a 
rather shallow groove. Their amino acid composition is believed to be biased with an 
unusually high percentage of asparagine, histidine(44,45), tyrosine(45,46) and serine(47),
although some variability exist in the literature. These analyses were performed when 
antibody structures were still relatively uncommon, and the datasets that were used 
may not have been widely representative. The conformational flexibility of antigen 
binding sites is 
also subject to 
debate, and 
examples of both 
key-lock and 
induced fit 
mechanisms have 
been documented. 
In the cases where 
conformational 
changes were detected, they involved sidechain rearrangements(48), movements of 
CDR backbone atoms, modifications to the hydration layer involved in antigen 
binding(49) and even shifts in the relative positions of the heavy and light chains(50,51).
The thermodynamic aspects of antibody-antigen interactions share many 
common points with protein-protein interactions in general, which may be one of the 
Figure 6: Topology of the all 6 immunoglobulin fold. CDR: 
complementarity-determining region. Immunoglobulin folds from the 
heavy and light chains face each other. The approximation of the CDRs in 
antibodies results in the antigen binding crevice. 
11 
reasons why antibody-antigen systems are often used in thermodynamic studies of 
protein interactions. The forces responsible for antigen binding are believed to be 
mediated primarily by van der Waals interactions, hydrogen bonding and occasional 
ion pairing. It is somewhat surprising considering the high affinity of antibodies that 
they would rely so little on the stronger ion pairing. However, contact surfaces of 
antibody-antigen complexes are usually very extended (commonly 600-900Å2)(52),
which allows for the accumulation of an accordingly great number of weak 
interactions which result in the strong affinity. As an increasing number of atomic 
resolution crystal structures were obtained, it became evident that water molecules are 
playing an important role in antigen interactions. The anti hen egg lysozyme antibody 
D1.3 was thoroughly used to characterize this phenomenon precisely (53,54). This 
experimental framework helped obtain a clear breakdown of the various energetic 
contributions to binding. Enthalpy contributions provided by direct binding of the 
antigen to the antibody or to interfacial water molecules were shown to offset the 
entropic loss resulting from increased order of the loops and of the solvent molecule 
network in the interface of the complex(55). In this particular system, the solvent 
entropy increase resulting from hydrophobic interactions was not found to provide a 
significant amount of energy to the system. Theoretical considerations based on 
numeric computations hypothesized that crystal structures could be underestimating 
the solvation state of antibody-antigen interfaces(56). The importance of this 
phenomenon was also highlighted by the finding that reorganizations of the 
interfacial network of water molecules were efficient enough to compensate the 
enthalpy losses inflicted by a mutation(57). Whether or not these considerations remain 
12 
true for other antibodies is unclear, but the results of this project will provide 
additional data addressing these questions. 
 
1.4. Calcium binding in coagulation factors and 
immunoglobulins  
 
1.4.1. Overview
Calcium is an extremely important element in bioinorganic chemistry. It is a 
crucial component of bone tissue, where it is present as calcium phosphate(58).
However, soluble forms of calcium also fulfill an impressive range of functions that 
are mostly mediated by inducing conformational changes upon binding to a variety of 
proteins. It is a ubiquitous intracellular messenger with roles including, but not 
limited to, skeletal or cardiac muscle contraction, vision, or gene regulation(59).
Calcium signaling is very rapid, because in a normal situation its cytoplasmic 
concentration is very low compared to its concentration in the cytoplasmic stores 
(mostly the endoplasmic reticulum) or in the extracellular or interstitial 
compartments. These gradients are taken advantage of to obtain fast concentration 
increases by opening ion-specific membrane channels. Once released in the 
cytoplasm, calcium binds to protein sensors of the EF-hand class such as calmodulin 
or troponin, resulting in a dramatically altered conformation which carries the effector 
functions. More importantly for this project, calcium is a key component in plasma, 
where its presence at levels of 2-3mM is necessary for proper function of the blood 
13 
coagulation pathway. This requirement stems from a variety of interactions that exist 
between calcium and the different domains constituting the protein factors of blood 
coagulation, particularly in the Gla domains, where the average Kd values are nearly 
millimolar. Finally, as our results unequivocally show, calcium can also bind proteins 
of the immunoglobulin fold to participate in a specific interaction with a protein 
ligand. In the present review we will only focus on the coagulation factors and on the 
immunoglobulin fold because of their relevance to the crystal structure that was 
obtained. 
 
1.4.2. Calcium binding to blood coagulation factors
Calcium binding to the Gla domain: An important number of reactions involved in 
hemostasis take place on the surface of the injured endothelium. This localization of 
the coagulation reactions is mediated by 
the interaction of a specific domain of the 
factors, the gamma carboxyglutamic acid 
domain (Gla domain) with the injured cell 
membrane. This domain is characterized 
by the presence of gamma 
carboxyglutamic acids, which are post-
translationally derived from the glutamate 
residues of the polypeptide precursor in a 
vitamin K-dependent reaction(60). It is 
Figure 7: Gla domain, from reference (62), 
pdb code 2PF2. Calcium atoms are 
represented as spheres, water molecules as 
crosses. The gamma carboxyglutamic acid 
residues are displayed as sticks. 
14 
found in coagulation factors II, VII, IX, X, protein C and protein S(61). The first 
crystal structure of this domain from prothrombin(62) revealed that the carboxy 
glutamic acid residues are involved in a network of interactions with 7 calcium ions, 
which results in the particular all-N domain illustrated on figure 7. Although the 
binding of calcium was at first thought to alleviate electrostatic repulsion between 
acidic residues of the Gla domain and the negatively charged membrane phospho-
lipids, it was later demonstrated that in the case of the Gla domain of factor X, 
important structural rearrangements take place upon calcium binding, that result in 
the exposure of hydrophobic residues(63). Similar findings were obtained for the Gla 
domain of protein C(64,65). Together, these data would readily explain the increased 
affinity for membranes of the calcium-bound form of the Gla domain. The interaction 
of calcium bound Gla domains with membranes is not the only function of this 
domain. In addition, it can participate in mediating protein-protein interactions that 
are functionally significant. For instance, the Gla domain of protein C enables 
specific interactions with both the endothelial protein C receptor(65,66) and the cofactor 
protein S(67).
Calcium binding to the EGF domain: The epidermal growth factor domain (EGF 
domain), found in proteins of the procoagulant, anticoagulant and fibrinolytic 
pathways, is a small, all-M protein fold which has in some instances the ability to bind 
calcium(68). This occurs in thrombomodulin(26) or protein S(69), the cofactor of aPC. 
The first EGF domain in protein C also has a calcium binding site, but its role in the 
function or conformation of the protein remains under study(70). The situation is very 
different in factor VII, where the occupancy of the EGF calcium binding site was 
15 
found to have an effect in mediating the interactions with tissue factor. Interestingly, 
this effect was only detected in the presence of the adjacent Gla domain(71). This type 
of interaction between a Gla and an EGF domain is also encountered in factor X(72),
although it was found that calcium can bind an individual factor X EGF domain(73).
Importantly, the mediation of protein-protein contacts by calcium in EGF domains is 
not limited to interactions with the Gla domain. This was demonstrated for one of the 
EGF domains of factor IX(74). In this particular X-ray crystallography study, the 
authors obtained a crystal form in which calcium mediates crystal contacts between 
EGF domains, thus illustrating the ability of calcium to mediate contacts between 
different EGF domains. Another example is the calcium binding site shared between 
the EGF-like domains 5 and 6 of thrombomodulin(26). The calcium-mediated binding 
of an EGF domain to a different domain is also encountered in proteins that do not 
belong to the coagulation factor family, such as the complement triggering protease 
C1s(75) or the extracellular protein fibrillin(74,76).
Calcium binding to the serine protease domain: Lastly, the catalytic domains of some 
of the blood coagulation factors also share a conserved trypsin-like calcium binding 
loop(61,77) spanning residues 70-80.  In many cases, calcium binding is required to get 
full activity. This is the case for example in factor VII(78-81), factor IX(82), factor X(83),
or protein C(84), although in some instances the presence of a calcium binding site on 
the substrates complicates the analysis. Importantly, prothrombin does not have a 
calcium binding site in the 70-80 loop. Instead, a lysine residue is present at position 
70, where an acidic residue is usually present, with its epsilon amino group occupying 
the regular calcium position. The resulting ion pair with the aspartic acid at position 
16 
80 further prevents calcium binding, and locks the loop in a conformation essentially 
similar to that encountered in other, calcium occupied 70-80 loops. Other coagulation 
factors that contain the serine protease domain however, are all characterized by 
calcium binding to the 70-80 loop.  
 Protein C, of which a fragment of the activation region is present in the 
structure that was obtained during this project, also has a calcium binding site in the 
serine protease domain(85). The occupancy of the calcium binding loop has a 
tremendous effect on both the activation rate(3) (fig. 4) and on the catalytic activity(84).
The effect of calcium on activation was demonstrated by kinetic studies, which 
revealed that calcium is a potent activator of the activation reaction catalyzed by the 
T-TM complex, but inhibits the reaction in the absence of TM(3). The effect of 
calcium was unequivocally proved to be mediated by a site in the serine protease 
domain. An E80K mutant of Gla-domainless protein C with an ion pair engineered 
into the putative Ca2+ binding site in the manner of thrombin/prothrombin(42) showed, 
in the presence of EDTA, the activation behavior of wild type protein C with Ca2+ 
bound. In addition, a proteolytic deletion of the Gla domain would not disrupt the 
calcium dependence of T-TM activation(85). This indicates that the ion maintains the 
serine protease in a conformation that is recognized by the T-TM complex, but not by 
thrombin alone. This effect is thought to be mediated through a conformational 
interplay that would occur between the calcium binding loop and the activation loop 
of protein C. Several experimental results favor this hypothesis. For instance, the 
introduction by mutagenesis of a tryptophan residue into the activation region 
dramatically increases the fluorescent properties of the protein in a calcium-
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dependent fashion(37). Alternatively, by replacing either of the two tryptophan 
residues naturally present in the calcium binding loop of protein C by phenylalanine, 
it was observed that the fluorescent properties usually seen in the wild type protein 
were lost(14). Theoretical modeling studies suggest that in the structure of the 
zymogen, the activation loop and the calcium binding loop may be in direct 
contact(17,40). Finally, the replacement of two aspartic acid residues present three 
positions away on each side of the scissile bond (positions 10 and 15 in the 
chymotryspin numbering scheme, or P3 and P3’ in the Schechter and Berger 
nomenclature(86)) by glycines decreases both the affinity of the serine protease 
domain of protein C for calcium, and the calcium requirement of the activation 
reaction by T-TM(39). Overall, the serine protease domain of protein C illustrates the 
importance that calcium-mediated conformations can have on the biological function 
of a protein. 
 
1.4.3. Calcium binding to proteins of the immunoglobulin fold
In contrast to the other examples provided so far, the immunoglobulin fold is 
rarely observed to bind calcium. The Fab molecule is a well populated example of 
structurally solved immunoglobulin folds, with 652 structures out of the 1512 
immunoglobulin structures available in the March 2007 release of the protein 
databank (PDB)(87). Among these 652 entries, only 24 (3.68%) have a 
crystallographic calcium, and only one (0.15%) has a calcium at the antibody-antigen 
interface(48). This unique structure is of the Fab of the monoclonal antibody Q-425, 
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directed at the human CD-4 receptor. Because of its singular relevance to the calcium 
dependence of HPC-4, this structure will be discussed here. 
 The authors obtained the structure of the Fab in the presence or absence of 
calcium. All crystals were obtained in the absence of antigen. As seen on figure 8, the 
calcium ion is located in the center 
of the antigen-binding crevice. The 
complex seen in the 2.9Å crystal 
structure has a relatively weak 
dissociation constant of 187µM, as 
measured by surface plasmon 
resonance. This relatively mild 
affinity is due to the fact that the 
coordination shell of the ion lacks 
three additional positions, hypothesized to be provided by the antigen. The antibody 
provides 4 atoms for calcium coordination, located one each in the CDR-H3, CDR-
L1, CDR-L2 and CDR-L3. Because of its central position in the antigen binding site, 
it is hypothesized that the calcium ion acts mostly as an electrostatic bridge between 
antigen and antibody. Contrary to what will be shown in HPC-4, no structural 
rearrangement is taking place in Q-425 upon calcium binding, as demonstrated by the 
absence of major changes between the calcium-bound and calcium-free structures. 
The backbone traces of these two structures are essentially similar (RMS for 
backbone atoms of 0.433Å), and the only significant sidechain rearrangement is a 
180° rotation of the CM-C bond in asparagine 100A. The functional character of the 
Figure 8: Q-425 antigen binding site. From reference 
(48), pdb code 2ADJ. Yellow: heavy chain; grey: light 
chain; red: CDRs. The calcium ion is represented as a 
green sphere. 
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calcium binding site seen in the Q-425 structure is emphasized by the several 
thousand fold increase in antigen affinity resulting from its occupancy. By surface 
plasmon resonance, the authors demonstrated that the strength of the interaction with 
calcium was responsible for most of this affinity improvement. They suggested that 
interfacial calcium was advantageous in this particular case to compensate the limited 
antigen surface available for binding due to heavy glycosylation.  
 The sensory domain of the Na+/Ca2+ antiport(88) is a different example of a 
functionally significant calcium binding site occurring in an immunoglobulin domain. 
This transmembrane transporter allows the flux of calcium out of the cytoplasm and 
is gated by the calcium concentration inside the cell. The cytoplasmic calcium levels 
are detected by the transporter through binding to the intracellular sensory domain. 
The structure of this domain (fig. 9) revealed that 4 
calcium ions were located at the C-terminal portion of 
the fold, held in place by an extensive network of 
interactions with acidic residues and water molecules. 
It is thus very different from Q-425 both in terms of 
calcium binding mode and function. Whereas calcium 
is found at the interface between Q-425 and its antigen, 
the ions found in the Na+/Ca2+ antiport sensory domain 
are fully coordinated by the immunoglobulin fold. The 
mode of binding is intimately linked to the function of 
each protein. In Q-425, calcium binding at the interface 
helps the formation of the antigen complex by 
Figure 9: The sensory 
domain of the Ca2+/Na+
antiport. From reference 
(88), pdb code 2DPK. Green 
spheres: calcium ions. 
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providing significant energetic contribution. In contrast, calcium binding to the 
Na+/Ca2+ antiport sensory domain likely induces a conformational change of the 
antiport which results in its activation(89). This second example is relevant to HPC-4 
in that it illustrates the flexibility of the immunoglobulin fold and its ability to adopt 
calcium-mediated conformational changes. In principle, such a mechanism could be 
expected for HPC-4, where binding of calcium to the antibody would mediate a 
structural rearrangement of the CDR loops that would result in a conformation with 
high affinity for the antigen. However, the mechanism could not be exactly similar 
for the following reasons. First, the sensory domain of the antiport is actually an 
immunoglobulin constant-like domain, and has two strands less than the antigen 
binding domains of antbodies. If binding of calcium were to occur in exactly the same 
fashion in HPC-4, the conformational changes would have to be transmitted through 
the flexible elbow region that separates the variable and constant domains in 
antibodies. Although not strictly impossible, this mode of action is unlikely. 
Furthermore, calcium was found at the C-terminal loops of the Ig domain in the 
sensory domain, but antibodies bind their antigen at the N-terminal side of the M sheet. 
Still, the sensory domain of the antiport illustrates the ability of the framework of M
sheets in immunoglobulins to support calcium-mediated conformational changes in 
the connecting loops.  
 The mechanisms of the Na+/Ca2+ antiport and of Q-425 may not be mutually 
exclusive even though they are quite different. HPC-4 may function according to a 
combination of the two, where calcium would both induce structural rearrangements 
in the antibody and increase the affinity of the interaction by providing binding sites 
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to both the antibody and the antigen. The structure of HPC-4 in complex with calcium 
and the peptide epitope described in the results section will shed some light on this 
particular point.  
 
1.5. Generation of antibody fragments by proteolysis 
 
1.5.1. Overview
Crystallization of intact antibodies has been performed only a very few times, 
and only once to date on the murine subtype of HPC-4, IgG1(90,91). The most 
significant obstacle preventing these macromolecules from being crystallized is 
believed to be the flexibility of the hinge region(92). This, in addition to the large size 
of antibody molecules, is the main reason crystallographic studies of antibody 
molecules are most often carried out on functional fragments from which the constant 
domain is removed. The first experimental goal of the project was thus to generate 
functional fragments of the antibody HPC-4 in quantity and purity sufficient for 
crystallization trials. Several examples of antigen-bound Fab crystal structures have 
been obtained by similar procedures(81,93-98), further supporting the feasibility of such 
a method to reach the goals defined by this project.  
 Established experimental conditions for the generation of Fab, Fab’ and Fab’2
fragments of antibodies are presented on figure 5. Briefly, cleavage of the antibody 
above the hinge region yield Fab fragments in a single step, whereas generation of the 
Fab’ fragments involves cleavage of the antibody below the hinge region in a first 
step, followed by selective reduction of the hinge disulfides. Fab’2 fragments can be 
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obtained by modifying the cleavage conditions so that the hydrolysis occurs below 
the hinge region, yielding a bivalent fragment. Although some evidence exists that the 
Fc regions of antibodies can have some effect on the antigen affinity of the binding 
site(99,100), it is generally accepted that the various antibody fragments generated by 
protease hydrolysis retain essentially the same binding properties as the antibody 
from which they derive.  
 A small number of proteases having broad specificity are able to cleave 
antibodies in relatively homogeneous fragments with antigen-binding capabilities. 
The choice of the correct protease to use is a delicate process, rendered more complex 
by the variability of the antibody sequences at the antigen binding site. By using a 
protease that is very specific for a given sequence or conformation, one ensures that 
the number of cutting sites on a given antibody will be limited, thus yielding 
homogeneous preparations of a small number of well defined fragments. However, 
the high specificity of a protease can also be a hurdle to overcome if the structure or 
sequence of the particular antibody has any unusual characteristic. Proteases with 
relatively low specificity such as papain or ficin are often selected for that purpose. 
On the other hand, the use of a low specificity protease must be accompanied with 
great caution to avoid the generation of inhomogeneous preparations following 
cleavage of the antibody at multiple sites. For instance, considering the reported 
amino acid preferences of the protease ficin(101,102), the antibody HPC-4 has a 
predicted ficin cutting site about every ten residues. As a result, the conditions for 
proteolytic cleavage of antibodies have to be adapted for each particular case due to 
the inherent variability of those molecules. However, some consistency in hydrolysis 
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conditions can be found among antibodies of a same isotype, due to their sequence 
similarities. In the case of the murine class IgG1 to which HPC-4 belongs, the use of 
the broad specificity protease ficin has been shown as optimal(103,104) although only a 
fairly small number of different IgG1 molecules were investigated. Digestion of IgG1 
by pepsin has been shown to be the least efficient among IgG subtypes 2, 3 and 2a(105).
Based on these data and on the existence of a ficin-based kit specifically designed for 
Fab and Fab’2 production from murine IgG, the initial condition for the digestion of 
HPC-4 was to use ficin.  
 The generation of Fab or Fab’2 fragments of mouse IgG1 can be performed 
using a commercial kit from PIERCE (“ImmunoPure”). However, although suitable 
for most biochemical applications, this kit has several design aspects that are 
incompatible with protein crystallography. This kit consists of a hydrolysis column 
onto which ficin is immobilized. The fractions eluted from this column are then 
submitted to a protein A chromatography that retains the undigested antibodies, but 
lets the fragments that do not contain a constant domain flow through. By design, this 
kit would be expected to dilute the sample quite noticeably, as the species of interest 
are always recovered from the unbound fractions. This mode of operation is 
inherently devoid of the concentrating effects associated with the self-sharpening 
elution fronts resulting from specific and saturable interaction of the species of 
interest and the column(106). Instead, it dilutes the sample by allowing it to diffuse 
freely into the buffer fronts that are used to displace the fragments of interest out of 
the ficin and protein A columns. In addition, the ficin column in the kit is operated by 
placing the sample onto the column, closing the column, and allowing the hydrolysis 
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to take place over a set period of time. This mode of operation limits the volume of 
material that can be cleaved to the void volume of the column, which requires starting 
with highly concentrated material or making many small batches, and thus increases 
the risks of variable cutting from batch to batch. In addition, the simple yet substantial 
operating parameter of enzyme concentration can not be optimized to control the 
extent of the hydrolysis reaction because it is fixed by the column properties.  
1.5.2. Experimental considerations for the use of ficin in HPC-4 hydrolyses 
Ficin is a thiol-protease with broad substrate specificity(101,102), and is 
activated by reducing reagents such as cysteine(101). The use of reducing agents in the 
hydrolysis solution is recommended to obtain maximal activity of the protease. 
However in this particular case, increasing the concentration of reducing agent can 
only be done to a limited extent. Indeed, the particular substrate that is targeted in our 
case has a total of 17 disulfide bonds(91,107), some of which are essential for the 
integrity of the fragments that need to be recovered. Obviously, an intermediate level 
of reducing potential must be found that allows a reasonable activity of the protease 
but avoids a denaturing reduction of the substrate and products of the hydrolysis. It 
must however be considered that a mild unfolding resulting from partial reduction of 
the antibody may be beneficial in uncovering previously cryptic sites on the antibody 
for cleavage, as in several documented cases(108-110).
Over the course of the project, different reducing agents were considered to 
sustain the activity of ficin. For instance, glutathione (GSH) was expected to provide 
the same equivalent reducing groups as a cysteine solution, but located on a larger 
molecule. The resulting steric hindrance was expected to limit access of the GSH 
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reducing groups to the disulfides of the antibody. As a consequence, the resulting 
reduction was expected to be milder at similar concentration than the reduction that 
would have been obtained if the thiol groups were present on a smaller molecule. On 
the other end of the reducing spectrum, the bifunctional agent dithiothreitol (DTT)(111) 
was expected to provide more reducing efficiency at comparable concentration 
because of its small size and of the two thiol groups present on the molecule. Other 
reducing agents encountered in the literature include beta-mercaptoethanol (M-
MA)(112), beta-mercaptoethylamine (M-ME)(113), metabisulfite or ascorbic acid(114).
The time and temperature also have a dramatic influence on the extent of the 
reaction. In particular, the temperature at which the hydrolysis is carried out has an 
important role by increasing the reaction rates through diminishing the activation 
energy differences according to the fundamental laws of thermodynamics. As such, 
temperature is an experimental parameter that can be used to operate on ficin activity. 
 The generated fragments were evaluated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) in order to estimate their size and purity. The SDS-
PAGE protocol involves a step where the protein sample is boiled along with the 
detergent. The presence of even a small amount of a reducing agent carried over from 
the hydrolysis reaction along with such high temperature induces a partial reduction 
of the generated fragments, and interferes with the estimate of size. Hence, it is 
necessary to perform the SDS-PAGE experiments both in native and in reducing 
conditions. For instance, the cleavage of the heavy chain can be monitored by 
following the disappearance of the 50kD band present in the reducing lanes. As will 
be seen, generation of the Fab fragments required some non-reducing lanes, as their 
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dissociation yields two 25kD fragments that can be indistinguishable from a cleaved 
heavy chain.  
 The integrity of the binding site of HPC-4 must be carefully monitored 
through the process to ascertain that the proteolytic step did not induce cleavage in 
this region. This consideration is paramount given the importance of structural 
integrity in the antigen-interacting site for our purposes. To that end, an affinity 
chromatography resin of immobilized HPC-4 linear epitope was used. In presence of 
calcium, the only fragments that are able to stay attached to the column during the 
washing step do so because their binding abilities to the epitope are undamaged. The 
choice of a hydrophilic material for the beads onto which the peptide is covalently 
immobilized ensures a low level of unspecific adsorption. Hence, this step represents 
an efficient way to control that the fragments generated are also functional. In 
addition, this resin efficiently separates the combining site-containing species from 
the various other fragments. The calcium-dependence of the antibody is used to elute 
the fragments with very mild elution conditions that include the calcium-chelating 
agent ethylene diamine tetra-acetate (EDTA). This is an advantageous feature of 
HPC-4, especially when considering the near irreversibility of other antibody-antigen 
interactions. This often requires the use of harsh elution conditions such as extreme 
pH or high concentrations of denaturing agents or chaotropes that are not always 
compatible with the easy recovery of properly folded proteins. Consequently, this 
column is very useful as a first step in the purification of the material. However, it is 
important to bear in mind that the Fab, Fab’, Fab’2 and full-length HPC-4 are equally 
27 
well retained. Hence, this step is essentially useless for the separation of these species, 
if they ever happen to be present in the same solution (see results).  
 Another important parameter for the reaction is the way it is stopped. 
Iodoacetic acid (IAA) is an alkylating agent that selectively modifies cystein residues, 
making it a useful inhibitor for ficin(101). However, due to its oxidative properties, it 
has to be avoided because the combining sites of antibodies are rich in tyrosine(46) 
which are prone to IAA oxidation. Any covalent modification to the antigen binding 
site could alter the properties of the fragments, and needs to be carefully avoided.  
 In the case of the generation of the Fab’2 fragments, the reaction is stopped by 
adding the sulfhydryl-specific alkylating agent N-ethyl-maleimide (NEM). The free 
cysteines as well as those present in the active site of ficin are quantitatively reacted 
by NEM, leading to an efficient arrest of the reaction. NEM was used on several 
occasions for similar puposes, and no spurious oxidation of tyrosine residues was 
reported(105,115).
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2.1. Generation of HPC-4 fragments 
 
2.1.1. Optimizations of HPC-4 hydrolysis and purification
The formation of protein crystals for structural analysis is a process that 
requires extremely homogeneous protein preparations. This requirement stems from 
the fact that the cohesive forces inside a crystal arise from the interaction of precise 
surface patches on each molecule within the crystalline lattice. Hence, an 
inhomogeneous protein preparation can not yield well diffracting crystals with a 
reasonable likeliness because the surfaces susceptible to form crystalline contacts are 
different from one molecule to the next, thereby preventing their ordered assembly. 
Thus, impure protein solutions often are associated with increased tendencies to 
assemble in a disorganized fashion (precipitation) in conditions of low solubility, 
rather than to form crystals. In addition, if one of the species actually forms a 
crystalline lattice, another species may act as inhibitors to crystal growth in the case 
where they can add onto the lattice but do not provide additional interaction surfaces. 
As a consequence, protein purity and homogeneity are paramount in protein 
crystallography. Because the different species of an inhomogeneous preparation may 
crystallize in very different conditions (a phenomenon used in some industrial 
purification processes(106)), inhomogeneous preparations also amount to smaller 
concentrations of each individual species, which would impair their tendency to 
2. MATERIAL & METHODS
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crystallize. Taken together, these reasons explain why sample purity and preparation 
homogeneity are much more important in protein crystallography than in most other 
biochemistry applications. A significant portion of the project was thus devoted to the 
development of robust hydrolysis protocols able to generate high amounts of pure and 
homogeneous HPC-4 fragments that would crystallize more readily.  
 The methodology that was followed was to test different hydrolysis methods 
in a systematic fashion. The nature of the fragments that were generated was assessed 
by SDS polyacrylamide gel electrophoresis (SDS-PAGE) and their function was 
tested using an affinity chromatography using immobilized antigenic peptide. 
Although a large number of conditions were assayed over the course of the project, 
we will only present the final, optimized protocols to obtain the Fab’2 and the non 
covalently associated Fab (“ncFab”). A condensed account of the steps having 
yielded these methods is given in the “results” section.  
2.1.2. Generation of the Fab’2
Ficin hydrolysis. Ficin (1.97mg/mL) was preactivated by incubation in 1.1mM 
cysteine for 30 minutes at room temperature as specified by the manufacturer. The 
activated ficin was then added to a HPC-4 solution that contained cysteine. The final 
concentrations were 0.386mg/mL (7.72µM) HPC-4, 1mM cysteine, 19.5µg/mL 
(0.78µM) ficin, 50mM Tris pH7.5 and 2mM EDTA pH 7.5, representing a molar ratio 
of approximately 10:1. The hydrolysis solution was allowed to incubate on ice at 4°C 
for 5 days. The reaction was stopped by addition of the alkylating agent N-ethyl 
maleimide (NEM) to a final concentration of 10mM. The solution was brought to 
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4mM CaCl2 so that the EDTA was neutralized and that enough calcium would be 
available for binding to the peptide affinity chromatography column. 
Peptide affinity chromatography. The hydrolysis solution was adsorbed to an affinity 
chromatography medium onto which the antigen peptide was covalently immobilized 
by primary amine-reactive chemistry. This adsorption took place directly on the 
packed column for 1hr at room temperature. Following adsorption, unbound material 
was removed by flowing equilibration buffer (400mM NaCl, 20mM Tris pH 7.5, 
4mM CaCl2, 0.02% Na azide) at a very slow rate until the OD at 280nm of the outlet 
was not detectably higher than the OD of the equilibration buffer. Then, elution 
buffer was fed to the column (400mM NaCl, 20mM Tris pH 7.5, 4mM EDTA, 0.02% 
Na azide) while collecting 300µL fractions. The amount recovered was estimated by 
measuring the absorbance at 280nm and assuming a mass absorption coefficient of 
1.72ml/(mg·cm). Fractions containing the highest amounts of protein were pooled for 
further use. Usual recoveries were in the 60-70% range. 
Protein A affinity chromatography. To remove the undigested HPC-4 molecules, the 
elution fractions of the peptide affinity chromatography were pooled and submitted to 
protein A affinity chromatography (PIERCE). Protein A is a bacterial protein with 
high affinity for the constant portion of antibodies, and is thus ideal for this particular 
application. The chromatography took place as indicated by the manufacturer. Briefly, 
the column was equilibrated in PIERCE binding buffer (composition not disclosed to 
customers), then the sample was absorbed. The column was then washed using the 
binding buffer, and the HPC-4 Fab’2 fragments were recuperated from these fractions. 
The column was regenerated by eluting the bound full-length HPC-4 using PIERCE 
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elution buffer (0.1M citrate pH3.0). Because they do not bind to the column, the Fab’2
fragments were significantly diluted by this purification step. Usual recoveries were 
in the 60-70% range (36-49% if considering the peptide affinity chromatography 
purification step).  
 
2.1.3. Generation of the ncFab
Ficin hydrolysis. The method was essentially the same as the one used to generate the 
Fab’2, with the only differences being the reducing agent (1mM dithiothreitol instead 
of 1mM cysteine) and the duration of the reaction (4 days instead of 5 for the Fab’2).  
Peptide affinity chromatography. The hydrolysis solution was batch-adsorbed to an 
affinity chromatography medium (20mL bed volume) onto which the antigen peptide 
was covalently immobilized. This adsorption took place under mild agitation for 3 
hours at room temperature. The duration of the adsorption was chosen to be much 
longer than the typical timescale of antibody binding kinetics to optimize the amount 
of material bound to the resin. Following adsorption, the loaded resin was packed into 
a glass chromatography column. Unbound material was removed by flowing 
equilibration buffer (400mM NaCl, 20mM Tris pH 7.5, 4mM CaCl2, 0.02% Na 
azide) at a rate of 2mL/min until the OD at 280nm of the outlet was not detectably 
higher than the OD of the equilibration buffer. Then, elution buffer was fed to the 
column (400mM NaCl, 20mM Tris pH 7.5, 4mM EDTA, 0.02% Na azide) at a rate of 
0.2mL/min while collecting 1.4mL fractions. The amount recovered was estimated by 
measuring the absorbance at 280nm and assuming a mass absorption coefficient of 
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1.72ml/(mg·cm). Fractions containing the highest amounts of protein were pooled for 
further use. Usual recoveries were in the 70-80% range. 
 
2.2. Generation of protein C variant 
 
2.2.1. General considerations
The crystallization of HPC-4 and HPC-4 fragments was also attempted in the 
form of complexes with protein C. As a vitamin K-dependent blood coagulation 
factor, protein C has a gamma-carboxyglutamic acid domain in the N-terminal 
portion of the light chain(116). The chelation of calcium by the Gla domains of 
coagulation serine proteases is thought to mediate interactions with injured cell 
membranes, thus assisting in the spatial localisation of coagulation reactions(117,118). In 
our case, the Gla domain was removed from the protein C used in our studies to assist 
in its crystallization by decreasing the number of separate domains of the protein. 
Importantly, the removal of the Gla domain was shown not to influence the kinetics 
of the activation by the thrombin-thrombomodulin complex in solution(85) or the 
binding to HPC-4(41). For that purpose, a variant of protein C that is devoid of the 
gamma carboxyglutamic acid (Gla) domain, GDPC, was used. Initially obtained 
though proteolysis(85), this variant can also be generated by plasmid expression in a 
mammalian cell host, as the material used in our study. 
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2.2.2. GDPC production methods
GDPC was expressed in HEK-293 mammalian cells expressing the sequence 
from a PL-4 plasmid, a generous gift from Dr. A. R. Rezaie. The cells were grown on 
the surface of a 10 stack Nunc cell factory (Sigma-Aldrich) with an operating volume 
of 2L of media supplemented with 5 to 10 % of bovine serum at 37°C under 5% CO2.
Every two days, the protein-rich media was drained from the factories and replaced 
with fresh media under sterile conditions. After collection, the collected media were 
supplemented with the reversible protease inhibitor benzamidine and sterilized by 
addition of sodium azide. Cells that had detached from the factory surface were 
removed by a “soft” centrifugation for 30 minutes at 3800rpm (4000×g at the bottom 
of the tubes). The supernatant of this centrifugation step was submitted to a “hard” 
centrifugation (30 minutes at 10000rpm, or 15300×g at the bottom of the tubes) to 
remove all cellular debris. The supernatant of the second centrifugation was pooled in 
4L batches (1 batch each 2 collections, or 1 batch every 4 days) and stored at 4°C 
until purification. 
 GDPC was extracted from the cell culture media using an affinity 
chromatography column where the antibody HPC-4 was covalently immobilized onto 
the chromatography beads. After adding calcium to a final concentration of 10mM, 
the media was batch-adsorbed with equilibrated resin overnight at 4°C under mild 
stirring (80mL media/mL resin; 50mL resin). The resin was then allowed to sediment 
for one hour, after which the cleared supernatant was removed. The remaining slurry 
was packed onto a glass column under steady flow of equilibration buffer (100mM 
NaCl, 20mM Tris pH 7.5, 3mM CaCl2, 10mM benzamidine, 0.02% sodium azide). 
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After equilibration in 3 bed volumes, the adsorbed protein was submitted to a high 
salt wash of 2 bed volumes in high salt buffer (1M NaCl, 20mM Tris pH 7.5, 3mM 
CaCl2, 10mM benzamidine, 0.02% sodium azide). The salt concentration was then 
brought back down and the benzamidine removed by extensive wash (3-5 column 
volumes) into low salt buffer (25mM NaCl, 20mM Tris pH 7.5, 3mM CaCl2, 0.02%
sodium azide). The extent of this last step was essential to remove any trace of 
benzamidine. Indeed, this compound has a very high absorption coefficient at 280nm 
that interferes readily with protein concentration estimates done 
spectrophotometrically. The GDPC was then eluted off the column by switching to a 
very mild elution buffer that differs from the previous buffer only by the presence of 
EDTA instead of calcium, and that is generally extremely mild compared to 
conventional affinity chromatography elution buffers. The elution (25mM NaCl, 
10mM EDTA pH 7.5, 20mM Tris pH7.5, 0.02 sodium azide) occurred at a flow rate 
of 8.2mL/hr in 5mL fractions. The protein concentration of the fractions was then 
evaluated by measuring their absorbance at 280nm with a 1cm light path, using an 
absorption coefficient of 1.6mL·mg-1·cm-1. Fractions with an absorbance greater than 
0.04 were kept at 4°C until further purification.  
 Once an estimated 10mg of GDPC were accumulated, the corresponding 
fractions were pooled and submitted to a mono-Q ion exchange step using an Äkta 
FPLC chromatography system (GE healthcare). The protein pool was loaded under a 
1mL/min flow rate (25mM NaCl, 20mM Tris pH7.5, 0.02% Na azide) while 
monitoring the 280nm absorbance of the eluate to detect column overloading. The 
column was then submitted to a linear gradient of NaCl concentration, sweeping from 
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25 to 600mM in 30mL under constant flow rate. Both the absorbance and the 
conductance of the eluate were monitored during the elution. 500µL fractions were 
collected, and peak fractions were pooled and stored at 4°C until formation of the 
complex for crystallization. 
 
2.3. Characterization of HPC-4 fragments 
 
2.3.1. Fluorimetry
The fluorescent properties of the naturally occurring amino acid tryptophan 
(and, to a lesser extent, tyrosine and phenylalanine) are often used as conformation 
probes in protein studies. Indeed, the fluorescent emission spectrum of these residues 
depends on the polarity field that surrounds them, which is modified whenever 
conformational changes occur within a given range. The measure of fluorescence 
intensity changes at a fixed wavelength or as fluorescence spectrum is often used to 
monitor an event that modifies the conformation of a protein. This technique has the 
advantages of simplicity of the setup and of high sensitivity. It is however dependent 
on the presence of a tryptophan residue in the vicinity of the conformational event, 
which must be present naturally or added by mutagenesis. In the case of HPC-4, the 
fluorescence emission between 305 and 400nm was shown to depend on the calcium 
concentration when a 12-mer epitope peptide is present(41). To assess the function of 
the ncFab fragments, fluorescence measurements were performed in increasing 
concentrations of calcium and in the presence of various concentrations of the 9-mer 
epitope peptide used in the crystallization studies.  
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Fluorescence measures were taken on a PC controlled SLM 8000 fluorescence 
spectrometer with high voltage parameters of 950V and 400V for the signal and 
reference channels, respectively. The titrations were carried out using a mixture of 
1µM ncFab and 0, 0.1, 0.5, 1.0, 2.0 or 4.0µM of epitope peptide. All solutions were 
made in 10mM tris pH7.5, 0.02% Na azide using chelex treated water to allow a strict 
control over the calcium concentration. The solutions contained 6kD polyethylene 
glycol to a final 0.1% to minimize the loss of signal by nonspecific adsorption on the 
walls of the cuvette. Titrations were performed by adding small volumes of 
concentrated calcium solutions to the cuvette inside the spectrometer. The excitation 
wavelength was set at 280nm, and the emission intensity was measured in a 16nm-
wide wavelength window centered around 340nm. With this setup, count rates were 
in the 20000cpm range, allowing a good sensitivity while operating well under the 
50000cpm maximum imposed by the saturation limit of the photomultipliers. After 
each addition of calcium, the sample was mixed by pipette reflux and allowed to 
equilibrate for at least 3min. The fluorescence intensity was measured during three 1 
minute periods with sample mixing in between and sampled at one measure every 3 
seconds (60 datapoints minimum). Shutters were closed at all times except while 
measuring to ensure minimal photobleaching. The signal intensity obtained with 
closed shutters was averaged over the length of the experiment and removed from the 
signal values with open shutter (black noise removal). The signal intensity was 
averaged for each calcium concentration, and corrected for dilution assuming a linear 
dependence between the ncFab concentration and the fluorescence intensity (Beer-
Lambert law adapted to fluorescence, valid for concentrations below 10-5M). The 
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fluorescence value F obtained at the various calcium concentrations was divided by 
F0, the fluorescence obtained in the absence of calcium. The value 10 FF was fitted 
to a single site binding model, as recommended(119):
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Specifically, equation (1) was linearized by considering the reciprocal: 
 
1
1
][
1
1 'max
2'
max0
0

+

	







=
 + FCaF
K
FF
F d (2) 
 
The experimental data (plotted as ( )00 FFF  against [ ]+21 Ca ) were submitted to 
linear regression using equation (2), and the value for Kd was calculated as the ratio of 
the slope 1'max FKd and the intercept 11
'
max F . This procedure was repeated at 
all epitope concentrations. 
2.3.2. Modeling of HPC-4
Further characterization of HPC-4 fragments was carried out in silico by 
building a molecular model. The immunoglobulin fold is characterized by a very 
small variability in sequence, which transcribes into accordingly small structure 
variability. Apart from the hypervariable loops and the elbow angle between the 
variable and constant domains, the structures of antibodies are usually quite similar. 
Thus, it was decided to map the sequence of HPC-4 on to the structure of a 
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resembling IgG1 in order to provide working hypotheses about HPC-4 function in the 
form of an approximate molecular model. The model was never intended to provide 
any reasonable accuracy at the atomic level, but rather to coarsely map out the 
positions of certain unusual features of the HPC-4 sequence. In particular, two 
stretches of electronegative residues are present in the sequence of HPC-4 at the 
CDR-H2 and CDR-H3. These were examined in more details to evaluate their 
potential as calcium binding sites. The antigen was not included in the modeling 
because no satisfying templates are available. An important consequence of this 
shortcoming in the modeling process was that by construction it would not be 
informative on the possibility of shared calcium coordination between HPC-4 and the 
antigen. However, before the discovery of the experimental structure described in the 
present work, the hypothesis of full coordination of calcium by the antibody was 
considered plausible, based on terbium fluorescence results(41) and on the apparently 
extremely low affinity of the epitope peptide alone for calcium. In this hypothesis, the 
binding of calcium to the antibody was believed to impart conformational changes in 
the antigen binding region resulting in a form with high affinity for the antigen, thus 
explaining the strong and mutual requirement for both calcium and the antigen to get 
ternary complex formation.  
 The antibody Mab61.1.3(91) (pdb code 1IGY) was used as template because its 
sequence is relatively close to that of HPC-4 (90.7% and 74.8% for the light and 
heavy chains, respectively), with most of the variations occurring as expected in the 
variable domains. First, the sequences were aligned using an EBLOSUM62 matrix 
and the MatcherP program(120). Then, using the program “MAIN”(121), the residues in 
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the Mab61.1.3 structure were successively changed into their counterpart in HPC-4 as 
predicted by the sequence alignment. When gaps or insertions occurred, backbone 
rearrangements were carried out, and the resulting segment was energy minimized.  
 Because of its hypothetical nature, and because the predictions it generated 
were partially proved wrong by the crystal structure, the model obtained will only 
briefly be described here, and will not be the object of a specific results section. Two 
candidate calcium binding sites were identified. The first involved the triplet of 
aspartic acid residues in the CDR-H2 region, which were modeled in a loop that 
would allow calcium binding without much backbone rearrangement. The presence of 
calcium at this location readily explained the tryptophan intensity changes that are 
observed upon calcium binding(41), because the triplet is located immediately after a 
doublet of tryptophan residues. The second identified possibility for a calcium 
binding site was the crevice between the CDR-H1 and the CDR-H3. Although it was 
less consistent with the  fluorescent properties of HPC-4, this hypothesis was closer to 
the truth, as the crystal structure later revealed (see results section).  
 
2.4. Crystallization 
 
2.4.1. Preparation of the complexes and buffer exchange
Formation of the complexes. HPC-4, HPC-4 Fab’2 and HPC-4 ncFab were mixed 
with solutions of GDPC or of the antigenic peptide so that molar ratios of 1.1 
GDPC/binding site or 1.5 antigenic peptide/binding site were obtained. The valency 
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of the antibody or antibody fragments was taken into account. The complexes were 
allowed to form in the presence of 15mM CaCl2.
Buffer exchange. Crystallization trials (screening) require protein solutions that have 
a salt content barely above the level required for solubility and that are very mildly 
buffered. Hence it was necessary to buffer-exchange the affinity chromatography 
elution pool into a “screen” buffer (20mM NaCl, 5mM TRIS pH 7.5, 5mM CaCl2, 
0.02% Na azide). A 25mL sephadex-based G-25M column that was extensively 
equilibrated in screen buffer was used for that purpose. Because the size of the pores 
on these beads is much smaller than even a small protein, but much greater than the 
buffering components, it acts as a de-salting step where buffer components are held 
up inside the pores, whereas protein are eluted much faster because their diameter 
prevents them from entering the pores. The complex pools were separated in fractions 
representing 40% of the resin volume. Each aliquot was loaded onto the resin, and 
eluted slowly while collecting fractions. The fractions having the highest absorbance 
at 280nm were pooled together and stored at 4ºC. Recoveries were usually in the 90-
100% range. Overall protein recoveries were about 42-53%, or 63-80% when 
computing in the necessary loss of the constant fragment of the antibody. 
 
2.4.2. Concentration
Protein solutions destined to be assayed for crystallization generally need to 
be in concentrations in excess of 10 g/L. The protein complexes obtained as described 
previously were submitted to centrifugal filtration on a 10kD MWCO spin filter 
(Millipore). This filter has a molecular weight cutoff sufficiently small to prevent 
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protein complexes from passing through. During operation, the quantity of protein 
atop the filter stays constant, while the volume decreases as the buffer is filtered 
through the pores by the effect of centrifugal forces, resulting in an increase in 
concentration of several fold magnitude. Concentration factors in the range of 60 
were routinely obtained with this setup, and allowed to reach protein concentrations 
in the order of 15-20 g/L. The diluted pools typically consisted of 30mL at an OD of 
0.45-0.50, and were centrifuged down to about 500µL.  
 To avoid nonspecific, irreversible adsorption of the protein sample on the 
filter, it is sometimes recommended to first pass a solution of dilute gelatin to block 
the nonspecific adsorption sites of the filter. In our hands however, it was found that 
the small loss of protein on the filter was preferable to the introduction of a protein 
contaminant associated with the gelatin pretreatment. This was especially important 
considering the importance of sample purity in protein crystallography. Furthermore, 
it was noticed that the maximum flow rate attainable was severely decreased with a 
pretreated filter. Consistently, the flow rate of the filtration decreased while the 
protein concentration was increasing. This observation could result from two 
effects(106). The first effect is the increase in retentate viscosity associated with the 
increasing protein concentration. The second effect that could explain this 
observation is concentration polarization. This phenomenon results in a localized 
gradient of protein concentration where the highest concentration is closest to the 
filter. In practice, it seemed that a film of highly concentrated protein was present on 
the filter at the end of the centrifugation step. One of the technical difficulties in using 
this type of filter is to recover the retentate quantitatively. Most of it can be recovered, 
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but a thin film always remains close to the filter. Because of the phenomenon of 
concentration polarization, one would expect that this thin film would be where the 
protein is the most concentrated. Hence, the concentration gradients still remaining 
above the surface of the filter were disrupted by mix-flowing the retentate with 
pipette refluxes, thereby equalizing the protein concentration in the bulk and in the 
thin film remaining after sampling. It is believed that this simple procedure can 
substantially improve the recovery of centrifugal filtration steps. 
 
2.4.3. Crystallization
Crystallization trials were performed using the hanging drop diffusion method. 
This experimental setup consists of a microwell plate (24 wells per plate) in which 
various crystallization solutions can be placed. The protein, initially present in very 
mildly buffered water (20mM NaCl, 5mM tris pH 7.5, 5mM CaCl2, 0.02% Na azide), 
is diluted 1:1 with the crystallization solution to be assayed. A 2uL drop of this 
diluted solution is deposited on a glass coverslip, and this coverslip is inverted and 
placed on top of the well and finally sealed using vacuum grease. After a period of 
time, a physico-chemical equilibrium is reached while water or other volatile 
molecules contained in the protein drop pass into the well solution through the vapor 
phase. Because of the great volumetric excess of the well compared to the protein 
drop (480µL:2µL in our case), the protein ends up in a solution whose composition 
closely approximates that of the well solution.  
 Importantly, this technique permits to determine the solubility behavior of the 
protein in a wide variety of crystallizing conditions without requiring any protein-
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consuming step of buffer exchange. An additional benefit of this technique is that it is 
easy to follow the changes in solubility by observing the drops with a microscope. In 
our case, the plates were examined immediately following setup, then daily for a 
week, then about weekly for longer periods of time. A Leica 95 binocular microscope 
equipped with polarizer was used for the observations. Because most of the drops 
equilibrate over days, the first week is the most important period to monitor carefully. 
Observations such as the type of response (heavy/light precipitate, phase separation, 
clear drop, presence of crystals) or the size of crystals if applicable were recorded. 
Interpretation of the drop results was considered with respect to biophysical 
considerations about protein crystallization (see results).  
 
2.4.4. Crystallization conditions database
Crystallization trials typically take hundreds of trials before a successful or 
even promising crystallization condition is found. In order to be able to keep track of 
all tested conditions in a quick and easy way, a program was created 
(“crystal_plates.py”), written in the python programming language (the source code is 
available upon request). As an input, this program takes a series of text files (one file 
for each crystallization plate) in which the composition of each well of the plate and 
other relevant information is written under precise but intuitive syntactic rules. Each 
time a new plate was set up, a corresponding file was written and saved. The python 
program actually consists of a graphical interface for easy retrieval of all the 
information relevant to a particular plate. In addition, the program can compile lists of 
recorded conditions matching a user-specified request from the data available to it on 
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all plates. The first benefit of this program was its ability to display the content of all 
wells of a specified plate in a friendly format. This feature was used to generate tidy 
and synthetic recording sheets on which microscopy observations were then reported. 
Analysis of the microscopy observations was then straightforward because the 
corresponding well buffer compositions were available at a glance.  
 The second and most useful feature of this program was its ability to search 
across all recorded plates for conditions that matched a request input by the user, and 
to output a list of the corresponding wells locations and composition (fig. 10). It is 
often the case that a small subset of conditions with a particular property (presence of 
a specific precipitant or precipitant combination, specific pH value or range,...) gives 
rise to a similar outcome in the protein drops of a single plate. It then becomes of 
interest to know which of the conditions tried on other plates also belong or resemble 
to this subset, and to assess whether the protein behaves with some kind of 
consistency across this subset. However, with hundreds of trials, this task is often 
impractical to do by hand, and can easily yield inaccuracies. The automated 
compilation of lists of conditions matching a user-specified request is an attractive 
Figure 10: Example output from crystal_plates.py. The program is displaying conditions 
containing ammonium and glycerol and a pH comprised between 5 and 6. 
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solution to this issue, and was used in several instances to rapidly map out phase 
diagrams that synthesized information collected from several crystallization plates. 
 It is often necessary to quickly compile a list of all conditions that contain a 
particular precipitant, or that have a certain pH value in order to identify trends in the 
solubility behavior of the protein. For instance, if a small subset of conditions hints 
that the protein may always precipitate when placed at pH values smaller than 5, it is 
very useful to be able to quickly generate a list of all conditions that have such a pH 
value.  
 
2.4.5. Macroseeding: theory & methods
The crystals obtained, described in “results”, were still too small to likely 
diffract X-rays in a significant manner. After having exhausted most of the usual 
optimizing methods for the growth conditions, we decided to attempt to apply the 
macroseeding technique(122,123). Macroseeding can be understood by considering 
crystallization as the two sequential events of nucleation and growth. The first event 
refers to the random formation of an assembly of several protein molecules into 
organized crystal nuclei of a critical size. The second event, growth, can occur if the 
solution is in a supersaturated state, corresponding to a protein concentration higher 
than the equilibrium solubility. If this is the case, then the presence of a nucleus can 
trigger the return to equilibrium by providing the energy barrier required to overcome 
supersaturation. In macroseeding, the critical nuclei are introduced into a drop of 
supersaturated protein (“target drop”) in the form of an already formed and individual 
crystal (“seed”). Crystals were transferred by using a nylon loop of a few hundred µm 
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in circumference. The addition of a seed to a target drop triggers the return to 
equilibrium by allowing supersaturated protein molecules to add onto the surfaces of 
the crystal that is provided, subsequently increasing its size. The procedure can be 
applied iteratively until the desired crystal size is reached. Prior to transferring the 
crystal to the target drop, it is recommended to mildly dissolve it (“etching”) so that 
the shell of protein that was added when the crystal stopped growing is removed. This 
procedure is believed to improve the characteristics of the surface of the seed so that 
protein molecules of the target drop can adsorb more easily. 
 The volumes of the growing crystals being macroseeded were measured over 
time. This data was applied to a mathematical model of macroseeding in order to 
derive a growth rate and other parameters characteristic of our system. The 
corresponding derivation is available in appendix X.1..  
2.4.6. Cryoprotection methods
The collection of protein crystal diffraction data is done at temperatures of 
about 100K for two main reasons. The first is to slow down the damaging process 
imparted on the protein molecules of the crystal by the radiative energy of the X-ray 
beam(124). The second reason is that in most of the cases, decreasing the temperature 
actually improves the diffraction characteristics of a given crystal. However, the 
water present in the crystal drop tends to form an expanded lattice of organized 
molecules upon freezing, which can be damaging to the protein lattice. To avoid the 
extraneous diffractions spots associated with the formation of ice, it is necessary to 
transfer the crystal into a solution able to freeze as amorphous glass rather than as 
crystalline ice. This process is referred to as “cryoprotection”. Several molecules can 
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be added to a water-based solution to cryoprotect it, such as glycerol, low molecular 
weight polyethylene glycol (PEG), alcohols or polyols. The method by which the 
crystal is transferred from the growth solution to the cryoprotecting condition also has 
some importance. It is possible to transfer it directly to a cryoprotecting solution drop, 
to have the crystal grow in a cryoprotecting condition, or to dialyze the growth 
solution against a cryoprotecting solution. In the case of direct transfer, the optimal 
timescale for transfer can vary from seconds to days, and the precise sequence of 
solutions through which the crystal is passed before being put in the final 
cryoprotecting solution has great importance on the outcome(125). Because all of these 
effects are mutually acting on the resulting diffraction characteristics of a particular 
crystal, the determination of the optimal cryoprotecting condition for a given crystal 
has to be done empirically.  
 The evaluation of a cryoprotecting protocol is often performed merely by 
assessing its ability to maintain apparent crystal integrity and by the quality of a 
diffraction snapshot obtained after cryoprotection. However, this method lacks proper 
control, since the quality of the obtained snapshot results not only from the 
cryoprotecting protocol that is assessed, but also from the inherent quality of the 
crystal. Indeed, even though two protein crystals can have identical aspects under a 
microscope, their diffraction pattern can vary widely, even in some cases for crystals 
that were grown in the same drop. As a result, a good cryoprotecting method could be 
discarded on the grounds of a poor diffraction pattern, when in fact it was the inherent 
quality of the crystal that caused the poor diffraction. To abrogate this source of 
variability, we used a two-step methodology to optimize the cryoprotection process. 
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A crystal was first mounted in its growth solution using a MicroRT mount system 
(MiTeGen, Ithaca NY) and an X-ray diffraction pattern was recorded at room 
temperature. The quality of the snapshot was used as an indication of the inherent 
quality of the crystal, thereby suppressing the crystal variability encountered when 
comparing cryoprotections performed on different crystals. The crystal was then 
submitted to the particular cryoprotection procedure being tested, after which an X-
ray diffraction pattern was recorded at 100K. The magnitude and nature of the 
differences observed between the diffraction of a given crystal before and after 
cryoprotection were used to compare the cryoprotection methods with one another 
without interference from crystal quality variablity.  
 Because none of the conventional cryoprotectants offered satisfactory results, 
we decided to investigate the small organic ion malonate. Although initially 
mentioned as a salt with uncommon propensity to crystallize proteins(126), malonate 
later became recognized as a cryoprotectant that is easy to use for protein crystals that 
are grown in high concentrations of ions(127). Malonate was expected to provide good 
results in our particular case, where the protein crystals had been grown in 
ammonium sulfate concentrations in excess of 1.6M.  
 
2.5. Structure determination 
 
2.5.1. Initial diffraction studies
Prior to the X-ray diffraction dataset that took place at the CHESS 
synchrotron, all X-ray related experiments were performed on the Rigaku rotating 
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anode copper X-ray generator of the Crystallography Program at the Oklahoma 
Medical Research Foundation. This device is equipped with a MAR345 laser readout 
image plate detector of 345mm in diameter. Although it is less powerful than a 
synchrotron source, this generator was amply sufficient for initial work. For shots 
made at room temperature, the loop containing the crystal was mounted on the 
goniometer, and exposed for 10 minutes.  
 The most direct method to determine whether a crystal seen in a drop is 
protein or salt is to mount it on a loop and observe its X-ray diffraction pattern. 
Because their unit cells are small, salt crystals typically yield very few diffraction 
spots which are separated from one another by great distances. On the opposite, 
protein crystals that have very large unit cells (commonly in the order of 10nm or 
more) yield numerous diffraction spots that are close to one another. Thus, X-ray 
diffraction can actually be used as a relatively quick assay to determine the nature of 
a crystal. In addition, it is advantageous because in the case of protein crystals, it 
provides initial estimates of the quality of the packing, the dimensions of the unit cell 
and the number of protein copies per unit cell. Over the course of the project, several 
apparently nice crystals were discarded on the ground of a poor diffraction pattern.  
 It has been reported in some instances that even though a protein crystal has a 
nice morphology as seen under a microscope, its diffraction characteristics are still 
poor. This can often be attributed to defects in the crystal packing that are not 
apparent using simply a microscope, such as crystal twinning on a microscopic level, 
or to crystal mosaicity. Considering this, testing a crystal on an X-ray diffractometer 
is so far the only valid test to determine how promising one crystal is in terms of its 
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potential use for structure determination. The choice is often difficult to make, 
because at this stage the crystals are not optimal in size, and hence even if they are 
packed perfectly, they are not expected to give rise to optimal diffraction patterns. 
Still, in our case the earliest diffraction patterns we obtained were searched for signs 
of twinning or generally bad packing quality. Importantly, the in-house diffractometer 
was also used to obtain accurate estimates of the space group of the crystal, the unit 
cell dimensions, and of the number of proteins present in the asymmetric unit. The 
minimum resolution attainable was also determined. Indeed, for reasons inherent to 
the physics of crystal diffraction, the highest resolution spots generally diffract with 
the least intensity. Since the average intensity of diffracted spots is directly related to 
the intensity of the incident beam, a crystal will diffract at a higher resolution at a 
synchrotron than at a rotating anode generator. Hence, the maximum resolution 
obtained at the OMRF X-ray diffractometer was used as a lower bound to the 
expected resolution of the synchrotron dataset.  
 Because it is sufficient for dataset collection, this X-ray source was also 
amply sufficient for evaluating the damages undergone by a crystal during a 
cryoprotection procedure. For instance if after cryoprotection a crystal is still intact 
enough to give an indexable diffraction shot, the unit cell dimensions were measured 
and compared to the values at room temperature. Any significant deviation from 
room temperature values was considered as indicative of an important rearrangement 
of the crystalline lattice. In general however, damages incurred during the 
cryoprotection were so extensive that the resulting diffraction pattern could not even 
be indexed.  
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 Finally, when the cryoprotection method was optimized, crystal candidates 
were screened on the rigaku diffractometer to determine which were the most 
promising and deserving of being sent to the synchrotron. That way, the time-
consuming step of crystal screening was already made when we arrived at the 
synchrotron, and the limited time available at the beamline was entirely used for data 
collection.  
 
2.5.2. Handling of crystals at cryogenic temperatures
For diffraction images made at 100K (at the synchrotron or at the rotating 
anode diffractometer), a propane-freeze procedure was adopted. Briefly, a bath of 
liquid nitrogen was setup, in which a 15mL eppendorf and a cryovial were put. Care 
was taken not to drop liquid nitrogen in the vessels. Gaseous propane was then blown 
into the 15mL eppendorf to condense it at liquid nitrogen temperature. At 
atmospheric pressure, liquid nitrogen is at its boiling point of 77.36K, or -195.8°C, 
which is just below the melting point of propane (85.5K, or -187.6°C). The propane 
blown was cooled by the walls of the 15mL tube, thus liquefying it for a short period 
of time (approximately 3-4 minutes) before freezing. During this brief period, the 
liquid propane was transferred to the cryovial, and the crystal mounted on the loop 
was rapidly immersed in the cryovial. The cryovial was then left in the nitrogen bath, 
effectively encasing the crystal in a shell of frozen propane. The crystals that are 
frozen according to this procedure can be stored in liquid nitrogen for extended 
periods of time. Specially insulated and secured dewars allow shipping the crystals at 
liquid nitrogen temperature. To mount such cryoprotected crystals, a thin layer of 
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propane was melted between the cryovial and the propane shell encasing the crystal 
loop by contact with the gloved hand. The vial containing the loop was then 
immediately attached onto the magnetic spindle (the loop is mounted on a magnetic 
base). Because of the thin layer of liquid propane lining the cryovial, the crystal loop 
(attached to the spindle) is now unfastened from the vial, but still encased in a shell of 
melting propane. This step is very important, because if the vial is removed while still 
fastened to the loop by solid propane, there is a risk of detaching the loop from the 
mount and to lose the crystal. The vial is then removed, exposing the frozen propane 
shell to the gaseous stream of 100K nitrogen. This procedure ensures that the crystal 
is maintained under 100K at all times because it is placed under the cryocooling 
system before the propane is fully melted. The temperature variations undergone by 
the crystal are thus minimized.  
 
2.5.3. Data collection
The interaction of light with the electrons of a protein crystal provides the 
information about the structure of the molecules present inside of it. In order to 
collect information on a length scale relevant to protein structure (10-9-10-10m), it is 
required to impart a radiation of matching energy, which corresponds to X-rays (10-8-
10-11m). Mostly two technologies exist to generate X-rays for macromolecular 
crystallography, which differ by their flux, brightness and brilliance. These 
characteristics are important because protein crystals are very small in size, and it is 
necessary to concentrate the radiation on a space of size comparable to that of the 
crystal. Furthermore, high resolution spots diffract with the least intensity, and the 
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most direct method to increase the resolution attainable with a given crystal is to use a 
greater impinging X-ray beam intensity.  
 As any electromagnetic radiation, X-rays can be obtained by accelerating 
charged particles. In a rotating anode type generator, the acceleration happens when a 
flux of electrons is stopped by a metallic anode within a vacuum tube. However, the 
resulting emission is anisotropic, which limits the flux of photons arriving on a 
particular area, and necessitates the use of optical elements to obtain proper 
collimation of the radiation on to the sample. The alternative to a rotating anode is to 
use the synchrotron radiation as an X-ray source. A synchrotron consists of a circular 
vacuum vessel of several hundred meters in circumference in which charged particles 
(electrons or positrons in this case) travel with a nearly relativistic velocity. To avoid 
collision of traveling particles with the walls of the synchrotron, it is necessary to 
accelerate them on a centripetal direction. It is this acceleration which results in the 
emission of X-rays in a geometrically well defined envelope, resulting in high 
brightness, flux and brilliance. Additionally, the electrons or positrons can be 
accelerated along a periodic trajectory when traveling down a straight section using 
special electromagnets, or “insertions devices” (wigglers and undulators). The energy 
spectrum of synchrotron radiation depends among other factors on the radius of 
curvature of the path of the particles, their velocity, and on the strength of the 
magnetic field used to provide the acceleration. With the setups of current facilities, 
synchrotron radiations have a very high flux, and are inherently very bright and 
collimated because of the precise control allowed over the trajectory of the electrons. 
This is very advantageous compared to rotating anode type generators for X-ray 
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crystallography applications, because it is necessary to irradiate the small volume of 
the crystal with the maximum amount of X-ray photons.  
 After necessary preparation(128), data collection took place at the Cornell High 
Energy Synchrotron Source (CHESS) at Cornell University, Ithaca, NY. We 
requested a time allocation at the F-1a hutch because it is well suited for crystals of 
small size. This particular hutch is 
located on a 24 pole positron 
wiggler insertion device. The X-
ray beam delivered to F-1a has a 
rectangular shape of 3.76mm in 
width and 0.944mm in height, with 
a radial divergence of 1mrad 
(horizontal) × 0.4mrad (vertical). 
The flux arriving at the sample is 
3.0×1011photons/sec. The diffracted rays are imaged with an ADSC Q4 charge 
coupled device. This hutch is equipped with a conventional cryocooling system with 
auto-refill capability. The spindle and the goniometer are fully servo-controlled, and 
the crystal centering is assisted by computer. The crystal centering program 
developed by CHESS displays a live image of the crystal overlayed with the position 
of the X-ray beam symbolized as a cross hair (fig. 11). By double-clicking on the 
position of the crystal at several spindle angles, the program sets the goniometer axes 
so that the crystal is always irradiated by the beam regardless of the spindle angle. 
Image collection is described in details in the results section. 
Figure 11: Photograph of the crystal loop being 
centered. The cross-hair indicates the center position 
of the X-ray beam. White bar: 100µm. 
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2.5.4. Structure solving
The process of structure solving from the raw dataset of diffraction pattern 
images obtained at various orientations of the crystal relative to the X-ray beam axis 
starts with the numeric process of scaling. This computation is necessary to bring the 
positions and intensities of the spots present on different images (spindle angles) onto 
a single frame of reference. The program DENZO(129) was used to that effect. 
 Unfortunately we were not able to optimize the crystal generation process 
enough to have heavy atom derivative crystals available for the synchrotron beam 
time allocated to us. As a result, direct phasing methods could not be applied, and the 
structure was thus solved by molecular replacement. In this phasing method, the 
phases of a different, structurally solved protein which shares high structural 
similarity with the protein that is studied are used as initial approximation. This initial 
approximation is then iteratively improved using the experimental dataset. This 
approach, although raising questions of model bias, is generally accepted as accurate, 
especially when as in our case, the structure is known to be close to that of the model 
used to generate the initial phase estimate. Because of its high level of sequence 
homology with HPC-4, the structure of the Fab MNAC13 (pdb code 1SEQ)(130) was 
used as search model. The translation and rotation of the search model into the 
measured unit cell for HPC-4 crystals was performed using the program AMoRe(131).
The variable and constant portions of the search model were separated in the input 
file to improve the Patterson search(132). This procedure allowed differences in elbow 
angle between 1SEQ and the final search model. The iterative unit of the refinement 
process was a reciprocal space refinement of the structure using the CNS suite(133),
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followed by a real space model building step using MAIN(121). The refinements were 
carried out with simulated annealing only in the first few rounds. At each step, 2Fo-Fc
and Fo-Fc Fourier difference maps were calculated by combining phases from the 
refined model and the intensities from the experimental dataset. The model building 
was carried out by fitting the atoms of the current model into maps contoured at 
1.0×[ (2Fo-Fc) and guided by 2.0×[ and -2.5×[ contouring of the Fo-Fc map. 
Periodically, a composite omit map was calculated and used in model building(134). At 
each step, the statistical values Rwork and Rfree(135) were used to evaluate progress and 
the quality of fit to the experimental data. When the R values were not significantly 
improved by further refinement rounds, the structure was submitted to rigorous 
geometry checks using the programs PROCHECK(136) and WHATCHECK(137).
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3.1. HPC-4 ficin hydrolysis 
 
3.1.1. Generation of Fab’2
Although a commercial kit is available from 
PIERCE (“ImmunoPure”), in our hands it did not 
yield satisfactory results when strictly following the 
manufacturer’s indications (fig. 12). One of the 
recommended cysteine concentrations actually 
generated the Fab fragment but it was obtained as a 
very fuzzy band, indicating the presence of several 
distinct cleavage products that may have been 
suitable for biochemical applications, but would 
unlikely crystallize very easily. In addition, the 
cysteine required to obtain proper cleavage in the ficin column was found to interfere 
with the integrity of the resulting fragments, as the 50kD fuzzy band obtained from 
the ficin column could not be retrieved again in the unbound fractions of the protein 
A column. This result was attributed to the reduction of the interchain disulfides. It 
was thus decided to replace the first step of the kit by hydrolysis using soluble ficin, 
which would allow a better control over all variables in the hydrolysis step. The 
hydrolysis was stopped by alkylating agents such as iodoacetic acid (IAA) or N-ethyl 
maleimide (NEM), providing the additional advantage of completely blocking the 
3. RESULTS
Figure 12: SDS-PAGE for 
PIERCE ImmunoPure kit. Lane 
1: starting material; lane 2: 
digestion mix; lanes 3,4: 
unbound fractions from the 
protein A column; lane 5: 
bound fractions from the 
protein A column; lane 6: 
molecular weights. 
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reduction of the sample that was observed initially using strictly the protocol of the 
kit. For the initial optimizations, the hydrolysis was set arbitrarily at 23h and room 
temperature as a starting point. The effect of reducing agent concentration was 
evaluated in a first step. The fragmentation patterns obtained around 1mM cysteine 
(fig. 13) revealed that there was no 
clear cysteine concentration threshold 
between the cleavage into either the 
100kD Fab’2 or the 50kD Fab 
fragments. This finding was somewhat 
surprising, because in the PIERCE kit, 
the reducing agent concentration is 
supposed to entirely determine the 
outcome of the hydrolysis in terms of 
the nature of the fragment that is 
obtained. In particular, no reducing agent concentration was found that would both 
result in the disappearance of the full-length HPC-4 band and limit the amount of 
50kD Fab generated. A reasonable middle point of 0.6mM cysteine was identified, 
which yields the Fab’2 as major product while almost entirely suppressing the full-
length HPC-4 band. However at this concentration there was already a detectable 
amount of Fab present, which would be hard to separate by conventional methods. 
Indeed, these fragments would be expected to be both equally unretained by the 
protein A chromatography and equally well retained by the antigen peptide affinity 
chromatography. Although it would be possible to separate them by gel filtration, this 
Figure 13: Effect of cysteine concentration on 
23hrs ficin hydrolysis at room temperature. 
Lane 1: starting material; lane 2: 0mM; lane 3: 
0.3mM; lane 4: 0.6mM; lane 5: 0.9mM; lane 6: 
1.2mM; lane 7: 1.5mM; lane 8: molecular 
weights. 
59 
strategy was not chosen because it is often associated with important dilution of the 
products. 
 The effect of temperature was then 
investigated at the previously identified 
cysteine concentration (0.6mM) in an attempt 
to decrease the amount of Fab generated while 
maintaining a good yield of Fab’2 produced. 
As seen in figure 14, decreasing the 
temperature dramatically limited the extent of 
the hydrolysis. It was found that after 4 days, 
the 100kD Fab’2 band was noticeably enriched, but no Fab was detected. 
Contamination by undigested 
HPC-4 was considered preferable 
than by the Fab, because it would 
be easier to purify using a step of 
protein A chromatography as 
recommended in the PIERCE kit. 
This condition was further 
optimized in terms of duration and 
cysteine concentration. A time 
series at 0°C in increasing 
concentrations of cysteine 
revealed that an optimum was 
Figure 14: Ficin hydrolysis timecourse 
at 0°C; 0.6mM cysteine. Lane1: starting 
material; lanes 2-7: days 1-6; lane 8: 
molecular weights.  
Figure 15: Affinity chromatography of the Fab’2
preparation. Top pane: elution profile of the column. 
Elution started at fraction 21. Lower pane: SDS-
PAGE. Lane 1: starting material; lane 2: hydrolysis 
mixture; lane 3: unbound fraction, lanes 4-6: elution 
fractions; lane 7: molecular weights. 
150kD 
100kD 
25kD 
1 2 3 4 5 6 7
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obtained between days 4 and 6 at 1mM cysteine. To ensure that the fragments 
obtained under these conditions were still functional, they were submitted to 
purification on the peptide antigen affinity 
column. As seen on figure 15, the fragments were 
very well retained by the column and recovered in 
a rather sharp elution peak, which was considered 
as indicative of a retained binding ability. The 
full-length HPC-4 that was obtained in the 
peptide column elution fractions was successfully 
removed using the protein A column of the 
PIERCE kit (fig. 16) and precisely applying the 
recommendations of the manufacturer.  
 
3.1.2. Generation of the Fab fragment
Attempts at generating the Fab fragments were made either directly or through 
reductive dissociation of the Fab’2 fragment obtained by the method previously 
developed. 
Dissociation of Fab’2 The Fab’2 fragments were brought to different concentrations 
of cysteine (1-10mM) and incubated for 1h at room temperature or at 37ºC. This 
method did not yield any detectable levels of dissociation. Increasing concentrations 
of cysteine (30-90mM) allowed us to obtain some dissociation, and resulted in a 
heterogeneous mixture of fragments grouped around 25kD and 50kD. This size 
heterogeneity as seen on non-reducing lanes was attributed to the partial reduction of 
Figure 16: Protein A purification of 
Fab’2 fragments: SDS-PAGE. Lane 
1: elution fraction form the peptide 
column (starting material); lane 2: 
unbound fractions; lane 3: bound 
fractions; lane 4: molecular weights 
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the intrachain disulfides. This was expected to yield fragments that would not be 
functional, so this method was no longer investigated. 
 
Direct hydrolysis: As a starting point towards finding suitable conditions for the 
generation of the Fab fragment by hydrolysis, the cysteine concentration was raised 
from the value used for the Fab’2. The goal was to increase the likeliness of reducing 
the disulfide linkages of the hinge region. A hydrolysis of 23h at room temperature 
with 7mM cysteine yielded appreciable amounts of the 50kD Fab and total 
disappearance of the Fab’2, but the preparation was heavily contaminated by a 
doublet of bands of approximately 25kD in size. These species were found also in the 
elution fractions of the epitope affinity column, possibly indicating their ability to 
bind specifically. Separation of these three species was attempted using a gel 
filtration chromatography on 
Sephadex resin G-75 (fractionation 
range for globular proteins: 3-
80kD). To improve peak 
separation, a bed length twice 
longer than the manufacturer’s 
recommendation was used.  
 
Unfortunately, a single elution 
peak was detected, and the two 
species were equally present 
Figure 17: G-75 fractionation attempt. Top pane: 
elution profile. Bottom pane: corresponding SDS-
PAGE. The starting material is shown on lane 1. Last 
lane: molecular weights. 
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throughout all absorbing fractions (fig.17). It was hypothesized that the 25kD bands 
were binding nonspecifically to the peptide epitope affinity column, and that they 
may be associated to it with a lower affinity. Thus, differential elution of the Fab and 
of the 25kD contaminants was attempted using variations of the wash buffer.  
As seen on figure 18 (top pane), buffers containing 2M NaCl or 2M NaCl and 0.5M 
of the chaotrope guanidine hydrochloride were not able to selectively detach the 
25kD fragments. Instead, the 25kD fragments were eluted as a single peak along with 
the Fab under regular elution conditions. Because the interactions may have been 
hydrophobic, the same experiment was repeated using a lower salt concentration 
(10mM) or by adding 
30%(v/v) ethanol to the 
wash buffer. These 
measures were aimed at 
decreasing the strength 
of the hydrophobic 
interactions with the 
column by decreasing 
the polarity of the 
solvent. Again, this was 
useless to selectively 
elute the 25kD 
fragments from the 
column, as all the 
Figure 18: Attempt at separating the 25kD fragments from the 
50kD fragment on the peptide epitope affinity chromatography 
column. Top pane: attempts at high solvent polarity. Lower 
pane: attempts at low solvent polarity. In either case, the 
elution peak contains the two fragments (not shown). 
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proteins came out as a single peak once calcium was replaced by EDTA (fig. 18, 
lower pane).  
 At this point, it became increasingly plausible that the interaction of the 25kD 
contaminants with the column was actually specific. Indeed, any nonspecific 
interaction would not be expected to be sensitive to mild variations in the chemical 
composition of the buffer such as the replacement of 4mM calcium by 4mM EDTA 
that triggered the release of the contaminants. Furthermore, the structure of the Fab 
fragment is in fact a disulfide linked dimer of two chains of molecular weights close 
to 25kD. It was thus hypothesized that the observed contaminants may actually be a 
reduced form of the Fab fragment or a form where the ficin cut occurs a little above 
the interchain disulfide bond. In the resulting form, the light chain and the cleaved 
heavy chain would not be disulfide linked, but would stay associated in solution 
owing to the extended surfaces of interaction that exist in antibodies. This hypothesis 
of a non covalent Fab, or “ncFab” was consistent with all of the experimental data. 
Indeed, the striking similarity in behavior regarding the interaction with the peptide 
epitope column tends to indicate that the two chains could form a functional binding 
site in a non covalent way that would be able to attach to the column. 
 The G-75 gel filtration results also contributed to this hypothesis, because the 
lack of separation may have been caused by the association of the two 25kD bands 
into a noncovalent assembly of 50kD in apparent molecular weight.  
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 It was thus decided to 
attempt to generate a pure 
solution of the ncFab. For 
that purpose, the more potent 
reducing agent dithiothreitol 
(DTT) was used to facilitate 
the reduction of the hinge 
disulfides. A hydrolysis of 
23h at room temperature was 
submitted to epitope affinity 
chromatography, and was 
insufficient to deplete the 
50kD species. Fortunately, it 
was rapidly found that 
depletion of the Fab in favor of the ncFab could be realized merely by keeping the 
DTT concentration at 1mM, increasing the hydrolysis duration to 4 days and 
decreasing the temperature to 0°C (see fig. 19). As a confirmation of the association 
of the two 25kD bands into a 50kD species, the solution obtained was submitted to 
molecular weight correlation using a dynamic light scattering apparatus. The average 
of 50 measurements of a solution having count rates in the 0.13-0.15s-1 range 
(acquisition time: 10s, signal/noise detection threshold: 2.5, assumed geometry: 
spherical) was found to be 47.6kD, in excellent agreement with our hypothesis. 
Intrinsic fluorescence experiments were later performed, and confirmed the proper 
Figure 19: Affinity chromatography of the ncFab 
preparation. Top pane: elution profile of the column. 
Elution start indicated by arrow position. Lower pane: 
SDS-PAGE. Lane 1: starting material; lane 2: 
hydrolysis mixture; lanes 3-4: unbound fractions, lanes 
5-6: elution fractions; lane 7: molecular weights. 
1 2 3 4 5 6 7
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function of the ncFab. Most conclusively, the 2.3Å crystal structure obtained also 
showed unequivocally the dimeric nature of the 25kD bands in the crystalline phase, 
and their non covalent association into a fully functional Fab form. 
 
3.2. Fluorescence titrations 
 
A typical 
fluorescence run is shown in 
figure 20. As seen on the raw 
data trace, the fluorescence 
signal increases when 
calcium is first introduced. 
This is consistent with the 
results for the full length HPC-4(41). The signal appears to decrease upon further 
additions of calcium, but this is only due to the dilution effect resulting from the extra 
volume of the calcium solution, as the corrected dataset shows. Figure 21 shows the 
calcium titrations made at various peptide concentrations. In the absence of peptide, a 
fluorescence intensity decrease of at the most 2% was observed. The significance of 
this decrease is unclear, but it could in principle result from the occupancy of a weak 
calcium binding site on the ncFab in the absence of peptide. In the characterization of 
the full-length HPC-4(41), the fluorescence intensity was also found to decrease in the 
absence of peptide, but with a higher magnitude (5%). The valency difference 
between HPC-4 and its ncFab may be at the origin of this apparent discrepancy.  
Figure 20: Typical fluorescence experiment. Shutters are 
closed except during measurements. Arrows: addition of 
calcium to 0.1, 0.2, 0.3, 0.9, 2.0mM CaCl2. NcFab 
concentration: 1µM; peptide concentration: 1µM. 
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 The titration of calcium dramatically increased the fluorescence signal of the 
ncFab in up to 2.0µM of peptide. This suggests the occurrence of a conformational 
change in the ncFab structure induced by calcium and peptide. This effect can not 
originate from a conformational change in the peptide, as it does not have any 
residues with significant fluorescence emission at the wavelengths used. The precise 
nature of this conformational change can not be determined by this experiment alone, 
but the crystal structure of the complex between ncFab, calcium and peptide obtained 
in the present project offers attractive hypotheses that will be discussed in the next 
section. Interestingly, this trend in maximal fluorescence intensity was only observed 
up to 2.0µM peptide. In the presence of 4.0µM peptide, the fluorescence increase is 
smaller. This could be the result of a weak binding of calcium to the peptide that 
Figure 21: Calcium-induced intrinsic fluorescence intensity changes of the ncFab in presence of 
various peptide concentrations. The ncFab was present at 1µM. Peptide concentrations are 
indicated. Kex=280nm; Kem=340nm. 
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would occur only at high peptide concentrations, scavenging it from productive 
interaction with the ncFab. This hypothesis is unlikely, as calcium binding to the 12-
mer epitope peptide used in the HPC-4 characterization was never detected. However, 
the 9-mer used in this study is devoid of a positively charged lysine residue present in 
the 12-mer, which would be expected to impair the ability of the 12-mer to interact 
with calcium.  
 The dissociation 
constant of the ncFab for 
calcium responded 
somewhat differently than 
the maximal fluorescence 
intensity (fig. 22). It kept 
decreasing at all peptide 
concentrations assayed, 
unlike the maximal 
fluorescence which 
reverted the trend at 4µM peptide. Generally, this indicates that binding of calcium to 
the ncFab is tighter in the presence of peptide. The highest calcium affinity, measured 
at 4µM peptide, was 8.6µM, in approximate agreement with the 6.5µM reported for 
HPC-4. These Kd values are not strictly comparable however, because they were 
obtained at 4 or 2µM peptide for the ncFab or the HPC-4, respectively. For reference, 
the Kd of ncFab for calcium in the presence of 2µM peptide was only 34µM. This 
difference may be explained by the highest avidity of HPC-4 over the monovalent 
Figure 22: Dependence of the Kd for calcium of the ncFab in 
the presence of various concentrations of peptide. The Kd
values were derived from fig.21 as described in methods.  
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ncFab. Still, the highest affinities reported for either HPC-4 or the ncFab are in good 
agreement. Overall, these results indicate that the binding of calcium to the ncFab 
may induce a significant conformational change in the presence of peptide. 
 
3.3. Crystallization  
3.3.1. Crystallization
Crystallization trials were 
done for the complexes of full-
length HPC-4 and GDPC, HPC-4 
Fab’2 and GDPC, HPC-4 ncFab 
and GDPC, and finally HPC-4 
ncFab and the antigen 9 residue 
peptide. All crystallization trials 
were made in the presence of calcium. Unfortunately, none of the GDPC-containing 
complexes yielded crystals or promising conditions, despite numerous attempts. The 
number of trials for each complex is represented in table 1. As a reference, a 
particular protein complex is generally considered difficult to crystallize after 400 
unsuccessful trials(138). In the absence of crystallization conditions, an iterative “edge 
search” approach was taken to tentatively identify conditions yielding 
supersaturation. In a first step, the conditions in which the protein precipitates or 
yields any type of phase separation were identified. A new series of trials were made 
with concentrations of the precipitating component evenly spaced from their initial 
concentration to zero. Observations made on this series effectively constitute a one-
Table 1: Summary of the crystallization trials
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dimensional, sparse-sampled phase diagram. On this diagram, it is then possible to 
identify two regions, one where the precipitant concentration is high enough that the 
protein changes phase, bordered by a second region where the protein stays in 
solution. Two successive concentrations yielding a different solubility response of the 
protein constitute a solubility edge. Because protein crystals grow out of 
supersaturated solutions, it is of interest to find the highest precipitant concentration 
that maintains the solubility of the protein. Such a concentration is high enough to be 
in the supersaturated region that enables the random event of crystal nucleation, but 
low enough not to lose most of the protein in a useless precipitated phase. A second 
set of trials was setup with precipitant concentrations in small increments evenly 
spaced within the previously identified solubility edge. The approach can be repeated 
for all the constituents of the initial condition, and is also to some extent applicable to 
pH. Although the cryoprotectant present in some conditions certainly affects the 
solubility of proteins, it was not generally used as a variable in edge searches in order 
to maintain the cryoprotection level of the initial condition. The successive 
application of this method on increasingly smaller regions of the solubility diagram 
and in response to all the components of the initial condition allows a precise 
characterization of the protein behavior. However, because crystal nucleation is 
kinetically governed when the protein is in the supersaturated region, it remains an 
inherently random event. The likeliness of obtaining protein crystals can only be 
increased by identifying a great number of different supersaturated regions. By doing 
so, one increases the odds of obtaining one condition where the kinetics of nucleation 
is favorable.  
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 Because crystals of the HPC-4 Fab in complex with calcium and the antigen 
peptide were obtained, this case will be developed here. The complex was assayed for 
crystallization using the commercial crystallization solution screens “Cryoscreen”, 
“Crystal screen II”, “Natrix”, “Membfac” and “Index” from Hampton Research. 
Crystals were obtained overnight in the index solutions number 4, 5 and 6 (2.0M 
ammonium sulfate buffered with 0.1M bis-tris 
pH 6.5, 0.1M hepes pH 7.5 and 0.1M tris pH 
8.5, respectively). The solutions at pH 6.5 and 
7.5 yielded small, spherical aggregates of 
needle-like crystals (fig. 24). The solution at pH 
8.5 yielded a shower of microcrystals. These 
solutions were recreated with our own 
chemicals, and similar crystals were obtained in 
the same length of time. 
 Because the presence of sulfate together with the calcium contained in the 
protein solution would likely enable the formation of calcium sulfate crystals, the 
nature of the crystals was evaluated. Fine-tuning a crystal growth condition is a very 
time-consuming and hands-on process, so it is important to determine the nature of a 
crystal beforehand to avoid spending time and reagents on optimizing the growth of a 
crystal that eventually turns out to be a trivial salt crystal. An ideal test would be to 
measure an X-ray diffraction pattern of the unknown crystal. However, this test 
would have been inconclusive in our case, because the small size of the crystal alone 
could have explained the absence of a protein-like diffraction pattern as well as would 
Figure 24: Spherical crystal 
aggregates obtained overnight in 
Hampton Index Screen condition 5 
(2.0M ammonium sulfate; 0.1M 
hepes pH 7.5) 
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have their actually being salt crystals. Hence, the following experiments and 
observations were made on these candidate protein crystals. 
 First, the crystallization trials were repeated using the protein buffering 
solution (20mM NaCl, 5mM tris pH 7.5, 5mM CaCl2, 0.02% Na azide) instead of the 
actual protein solution. Because this solution contains as much calcium as the protein 
solution but no protein, the presence of crystals with a morphology similar to that 
observed in the initial solutions would likely have indicated that these were in fact 
calcium sulfate crystals. No crystals were observed in these drops after 2 days. 
However, this experiment was not sufficient to prove the protein nature of the crystals. 
The presence of high protein concentration is expected to lower the chemical activity 
of the water, and hence it could potentially decrease the solubility of calcium sulfate. 
In other words, it was still plausible that the presence of high protein concentration is 
required to trigger the crystallization of calcium sulfate. Replacing the protein 
solution by plain calcium-containing buffer is therefore not a strict control, because 
both the presence of protein and the chemical activity of the water solvent are altered. 
The absence of crystals was a promising indication, but could still have been 
attributed to the differences in chemical activity between the initial condition and the 
test condition.  
 A second test was performed using Hampton's “Izit” dye solution. This dye 
takes advantage of the fact that salt crystals are packed much more densely than 
protein crystals, and are devoid of large solvent channels within the crystalline lattice 
unlike typical protein or biomolecular crystals. The molecular weight of this blue dye 
is engineered to be able to diffuse into pores as small as the typical diameter of the 
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solvent channels found in protein crystals. Hence, provided that the dye solution does 
not interfere with the solubility of the crystal, any color uptake by the crystal 
indicates diffusion of the dye into the solvent channels, strongly indicating that the 
observed crystal is a protein crystal. Two dilutions of the dye (undiluted or diluted 10 
times in water) were added to a drop that contained the undetermined crystals. The 
addition of dye immediately dissolved the crystals. The drops were then allowed to 
equilibrate with the reservoir solution. After 12 hours, crystals grew back from 
solution with a vivid blue color. As a control, calcium sulfate crystals were grown and 
the drops colored with the same dye. These crystals had a different morphology 
(longer and thinner needles), did not dissolve upon addition of the dye, and did not 
take up the blue color of the dye. Although this result strongly indicated that the 
crystals were not salt crystals, they did not demonstrate that the crystals contained the 
protein complex. It is known that small peptide crystals can form that have relatively 
high solvent content compared to salt crystals, so the remote possibility that the 
crystals were actually crystals of the antigenic peptide could not be rigorously 
dismissed. Furthermore, the izit dye had previously been demonstrated to permeate 
into crystals of peptide as small as 21 residues long, but not in crystals of a 6-mer or 
smaller peptides(139). In the case where the peptide would have dissociated from the 
antibody (for instance if the excess sulfate present had decreased the concentration of 
free calcium in solution to such an extent that the antibody would lose its affinity), it 
could in principle have crystallized as a crystal with solvent content high enough for 
the izit dye to be able to permeate. Still, the observation that the izit dye was able to 
permeate inside the crystalline clusters was a strong indication that they were in fact 
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the expected crystals of the HPC-4 ncFab, presumably in complex with calcium and 
the antigenic peptide. 
 Because the packing interactions of a protein crystal are very different from 
those of a salt crystal, the mechanical properties of these two types of crystals are 
very different. Salt crystals tend to be very resistant and brittle, and break into well-
defined shards when stressed above failure. Protein crystals tend to behave 
mechanically more like a hydrogel, being degraded throughout the stress range 
applied. A simple mechanical stimulation of an undetermined crystal with a needle 
under a microscope can often provide invaluable information about its nature. The 
crystals obtained were submitted to this test. They disintegrated upon contact with the 
needle when an amount of pressure considerably smaller than that required to break 
calcium sulfate crystals was applied. The crystal fragments that were obtained did not 
have the same aspect as the originating crystal, and resembled a typical protein 
precipitate instead.  
 Finally, the 
content of the crystals 
were assessed by gel 
electrophoresis. 30 
crystalline clusters were 
harvested from the 
originating drop, and 
were rinsed multiple 
times in reservoir solution 
Figure 25: SDS-PAGE of dissolved crystals. Lane 1: protein 
solution used to grow the crystals; lane 2: molecular weights; 
lane 3: crystallization buffer; lanes 4-7: solutions used to rinse 
the crystals; lane 8: dissolved crystals. 
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to avoid contamination by the initial protein solution that contained them. The 
crystals were then dissolved in SDS-PAGE migrating dye, boiled, and submitted to 
gradient gel electrophoresis. As controls, the wash solutions and the protein solution 
used to obtain the crystals were also put on the gel. As can be seen in figure 25, only 
the lane containing the dissolved crystals had protein bands, and the protein bands 
matched exactly those obtained with the protein complex solution. This last test 
unequivocally established the protein nature of the crystals. 
 Although promising, these crystals were still too small to diffract X-rays 
sufficiently to evaluate their potential usefulness in structure determination. Indeed, in 
some instances, the packing of a protein crystal can be too poor to provide reliable 
diffraction data even if the crystal has an apparently good morphology. The 
interacting effects of ammonium sulfate concentration, buffering molecule and pH 
were then evaluated. Crystals with better morphology were obtained using bis-tris at 
pH 6.5 as buffering agent, and by decreasing the ammonium sulfate concentration to 
the 1.70-1.85M range. Because these optimized crystals were still too small, it was 
decided to further improve them by macroseeding. 
 
3.3.2. Optimization of macroseeding procedure
The solubility pattern of the HPC-4-peptide complex was established in 
conditions close to the nucleating condition. In the cases where clear drops were 
obtained, it was determined if they were undersaturated or supersaturated by 
transferring a small crystal of defined size. The dissolution or decreased size of the 
crystal after an incubation period was taken as an indication that the drop was 
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undersaturated. If the crystal grew in size, or yielded the formation of additional 
crystals in the drop, the condition was considered supersaturated.  
 An important and recurrent problem was the appearance of new small crystals 
in the target drop after seeding. The crystals would appear either independently from 
the seed (“secondary nucleation”), or would directly grow off of the surface of the 
seed, but in incorrect orientations (“sprouts”). These small crystals were considered 
deleterious because they diverted some of the protein molecules away from the seed, 
thus decreasing its rate of growth. In 
addition in the case of sprouts, the quality 
of the seed itself was decreased so much 
that their diffraction pattern would 
worsen.  
 Secondary nucleation (see fig. 26) 
was attributed to the accidental transfer of 
microscopic crystal nuclei along with the 
principal seed during macroseeding. It could be almost entirely prevented by 
implementing a washing step into an ammonium sulfate concentration of 1.5-1.7M. 
Because this range of concentration does not allow the nucleation of crystals or even 
support preexisting crystal growth, it was hypothesized that the crystals put in 
presence of this solution would dissolve. Because of its size, the seed was only 
dissolved to a small extent (relative to its total size), but small crystals and nuclei 
were entirely dissolved, thereby decreasing the amount of secondary nucleation 
induced by their introduction into the supersaturated target drop. It was important not 
Figure 26: Example of secondary 
nucleation. Small crystals (A) divert 
protein away from the main seed (arrow). 
White bar:100µm 
A
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to leave the crystals for extended periods of time in the wash solution, because they 
tended to shatter in large fragments after a few minutes of wash time. 
 Appearance of sprouts (see fig. 27) was 
attributed to the presence of some sort of defects 
on the surface of the crystals, which would act as 
nucleation centers inducing the addition of protein 
molecules onto a lattice of a different orientation 
relative to the seed. First, the implementation of 
the washing step, although efficient to suppress 
secondary nucleation, seemed to actually increase 
the number of sprouts. The addition of 10mM CaCl2 to the washing solution resulted 
in a more efficient washing that yielded dramatically less heterogeneous surface 
nucleation. This observation was also considered as indicative that the HPC-4 present 
in the crystal was still saturated in calcium despite the high ammonium sulfate 
concentration. Interestingly, the presence of calcium allowed much longer wash times 
than previously, when they were limited by crystal shattering from its core. It would 
indeed be expected that the transfer of a calcium-containing crystal to a drop lacking 
the ion would induce the dissociation of calcium from the protein of the crystal by 
mass action. The resulting heterogeneity of protein in the crystal could likely cause 
the shattering of crystals occurring in calcium-free wash solution that was observed. 
The partial dissociation of calcium from the protein copies located on the outermost 
shell of the crystals would also likely yield patches of calcium-free copies of the 
protein from which the heterogeneous crystals could grow. In any case, the 
Figure 27: Sprouting. Arrows: 
sprouts growing off of the main 
seed. White bar: 100µm 
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differential responses obtained in the presence or absence of calcium were an 
indication that the crystals were actually saturated with calcium, and hence probably 
also with the peptide antigen.  
 A second source of sprouting was the mechanical manipulations of crystals. 
The crystals were relatively fragile, and shattered very easily upon application of a 
very mild mechanical stress. Although the nylon loops that were used for 
macroseeding were flexible, any contact of the loop with the crystal might still be 
expected to create surface defects. This source of sprouting was unavoidable even 
when using loops much bigger than the size of the crystal because it was often 
necessary to gently pull the crystal with the loop to have it escape the surface tension 
of the originating drop. Sprouts were also sometimes mechanically dissected from the 
seed, with some success if the dissection was followed by an extended wash. 
However, dissection of sprouts generated additional surface defects in an 
incontrollable manner that could not be removed even after extended wash. Once this 
was noticed, the presence of 
sprouts was used as a signal to 
consider stopping the iterative 
macroseeding of a particular 
crystal.  
 Despite these problems, 
several crystals were amenable to 
dramatic increases in size, as 
shown in figure 28. The rate of 
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Figure 28: Time course of crystal volumes during 
macroseeding-assisted growth. Crystals were too 
small at day 1 to be accurately measured. The points 
represent an average calculated from 6 crystals. Bars: 
standard error on the average value.  
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macroseeding growth, as defined and derived in appendix X.1., was of 6.1µm·day-1,
or 6.8 µm·day-1 when considering a decay of 70 days (also defined in appendix X.1.). 
Final sizes of 40-50×40-50×700-800µm3 were usually obtained over 5 macroseeding 
iterations. Increasing the number of macroseeding iterations invariably increased 
sprouting problems, thus limiting the final size for the crystals. The decision to stop 
macroseeding cycles was quite arbitrary because the appearance of sprouts was 
somewhat unpredictable. Crystals with cross sections as small as 40×40µm2 routinely 
yielded diffraction patterns nearly good enough for data collection. Thus, this 
particular threshold was considered as a minimum. Crystals yielding sprouts before 
reaching this threshold were mechanically dissected for one or two macroseeding 
rounds and discarded if sprouts persisted. Macroseeding of crystals bigger than this 
threshold and devoid of sprouts was considered very carefully, and performed with all 
the precautions possible. 
 Many crystals had a thickest part at the center of their long axis, and had a 
cross sectional area that decreased mildly and smoothly towards the extremities. 
These crystals usually had excellent diffraction patterns and were less prone to 
sprouting. If left equilibrated for days after the last macroseeding step, they would 
slowly fill until a fully prismatic geometry was adopted. 
3.3.3. Cryoprotection
Cryoprotection trials were made by taking a reference room temperature 
diffraction pattern of a crystal, transferring it from their growth solution to a tested 
cryoprotecting solution, taking a new diffraction shot at 100K and comparing the 
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diffraction properties before and after the cryoprotecting treatment. This procedure 
eliminated the crystal to crystal variability from the list of experimental unknowns.  
 Initial attempts were made using the conventional cryoprotectant glycerol, 
brought at a concentration of 30% in the macroseeding buffer. Although good 
amorphous glass formation was obtained merely by quickly dipping the crystal in the 
cryoprotectant, its diffraction pattern was of dramatically worse quality than before 
treatment. This was attributed to the partial disruption of the crystalline lattice by the 
important osmolarity gradients bound to occur during the brief equilibration period. 
Hence, a gradual replacement of the macroseeding solution by the cryoprotecting 
solution, based on a published method(125), was adapted. A drop of the macroseeding 
solution was deposited onto a coverslip, and the crystal was transferred to this drop. 
Then, while monitoring the crystal under the microscope, a small volume of the 
solution was removed and replaced by the same volume of the cryoprotecting 
solution, effectively increasing the cryoprotectant concentration surrounding the 
crystal. This operation was repeated several times until the initial macroseeding 
growth solution was significantly diluted into the cryoprotecting solution. This 
technique has the advantage of limiting the mechanical manipulation of the crystal, 
and also to allow a precise control of the cryoprotectant concentration profile 
throughout the procedure. A simple series analysis of the drop composition with 
respect to the cryoprotecting agent can be used to demonstrate that the concentration 
time profile can be precisely operated with the following variables: the wait period in 
between solution replacements; v, the volume of solution that is replaced at each step; 
V the total volume of the drop; Cf the concentration of cryoprotectant that is used in 
80 
the exchanges and n, the number of exchanges performed. The simple derivation in 
appendix X.2. shows that the concentration at the n-th step is obtained by the 
following expression: 
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In practice, it was found that evaporation of the drop was negligible only when the 
drop volume V was sufficiently large. A volume of 10µL was estimated sufficient for 
a total exchange time of 10 minutes or less. The concentration Cf was determined 
empirically for each cryoprotectant by immersing an empty loop into various 
concentrations, and fixing the loop onto the X-ray diffractometer with the cryostated 
nitrogen gas stream system on. The quality of the cryoprotection was estimated 
visually by the clear or hazy aspect of the drop or by the formation of ice crystals. As 
equation (X.2.6.) predicts, at fixed V and Cf, the highest concentration step increase, 
occurring in the first step, is dictated by the volume v. This volume was set at 2µL, so 
that the steepest gradient would only be to go from 0 to 20% of the final 
cryoprotectant concentration. Plots of (X.2.6.) were also used to determine that under 
these conditions, 22 steps are required to obtain an effective concentration in the drop 
of 99% of Cf. Unfortunately, adopting this step-increase protocol did not improve the 
cryoprotection, maybe because the 20%×Cf (amounting to 6% in glycerol 
concentration) initial concentration increase was still too high for the crystalline 
lattice to withstand. A smaller value for Cf of 20% was also tried using the step 
increase method, because this Cf was still cryoprotecting and because the highest 
concentration increase would only amount to 4% in glycerol concentration, which 
may have been less damaging to the lattice. This did not prove to be helpful either. 
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Observations made during the optimization of the crystal growth conditions indicated 
that the presence of even small concentrations of glycerol impaired the nucleation, 
growth rate and the morphology of the crystals. This observation was an indication 
that glycerol may improve the solubility of the protein, or in other words be 
disruptive for a crystalline lattice. If this hypothesis were correct, it would mean that 
regardless of its final concentration, glycerol would never be a successful 
cryoprotectant for this crystal. Thus, other shapes of gradients that could have been 
obtained by varying v and Cf at each step were not investigated because crystals were 
in short supply.  
 Instead, the effects of different cryoprotectants were assessed because the 
differential sensitivity of crystals to cryoprotecting agents is widely accepted(124). The 
organic solvent paratone was assayed. This petroleum derivative is transparent to X-
rays, and does freeze as a glass. Because paratone is not miscible with water, it is in 
principle possible to maintain the crystal in its growth solution within the drop of 
cryoprotectant. However because of its high viscosity, it proved difficult to transfer 
crystals without breaking. Another difficulty was to thoroughly remove the thin film 
of water that surrounds the crystal within the oily phase. This was required to prevent 
ice formation outside the crystal. Finally, paratone did not prove effective in 
cryoprotecting the crystals, presumably because the water remaining in the growth 
solution present in the solvent channels of the crystal had expanded while cooling to 
an extent that was damaging to the crystalline unit. 
 For reasons discussed in the methods section, the small organic acid malonate 
was used. It was determined that concentrations in excess of 3.2M were required to 
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obtain the cryoprotecting effect. As a safety precaution, a concentration of 3.4M was 
adopted. A quick dip in 3.4M malonate did not suitably cryoprotect the crystal. 
However at the macroseeding pH of 7.5, the majority of the malonate molecules have 
both their carboxylic acid functions dissociated. The resulting negative charges make 
it a potential calcium chelator. With such a high concentration, even if the acid 
functions are neutralized by sodium and even if the calcium has a low affinity for 
malonate, the mass action may be sufficient to dissociate the calcium present in the 
crystal. This reasoning was invoked to explain the poor diffraction of the crystal 
cryoprotected by a quick dip in malonate. To test this hypothesis, a similar procedure 
was attempted but using a malonate solution supplemented in a calcium concentration 
matching that of the 
macroseeding 
condition.  
 As seen on 
figure 29, this simple 
measure dramatically 
improved the 
diffraction properties 
of a frozen crystal, 
and quick dip in 3.4M 
malonate and 10mM 
calcium was selected 
as the definitive 
Figure 29: Cryoprotection. A,B: diffraction of a crystal before and 
after rapid dip in 3.4M malonate; C,D: diffraction of a crystal before 
and after rapid dip in 3.4M malonate + 10mM CaCl2. Diffractions A 
and C were obtained at room temperature; diffraction B and D were 
obtained at 100K.  
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cryoprotection procedure for the crystals. The differential behavior of the crystals in 
response to the presence or absence of calcium was considered a promising indication 
that they were in fact constituted by the calcium-bound form of the antibody. Despite 
the fact that the crystals were grown in the presence of calcium, the presence of the 
ion inside the crystalline lattice was not a certainty because the high concentration of 
sulfate present in the crystallization condition could still have driven the calcium 
away from the complex forming the crystal. 
 3.4. X-ray crystal structure 
3.4.1. Diffraction data collection
A total of three diffraction datasets were collected on a single crystal at a 
wavelength of 0.9128Å. The “STRATEGY” program was used to determine the most 
advantageous range of spindle angles to expose in order to obtain the best 
completeness. The position of the crystal inside the loop, and the resulting orientation 
of the crystal relative to the beam unfortunately yielded consequent blind regions of 
diffraction. Nevertheless, a total predicted 99 % completeness was expected. The first 
173 frames were collected on the central part of the crystal, with 40s exposures over 
spindle oscillation angles of 0.5°. Heavy radiation damage was visible at the end of 
this collection before the full intended angle sweep was reached, as a bright area on 
the live image of the crystal and a mild decrease in number of high resolution 
diffraction spots. The spindle was then moved to the right extremity of the crystal (in 
the orientation shown in fig.11), where a second dataset of 421 images was taken. For 
reasons attributable to the quality of the crystal in this particular area, the resolution 
of this dataset was not very high. It was not included in the set of intensities used in 
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the structure solving process. The spindle oscillation angle was maintained, but the 
exposure time was decreased to 20 s to slow down radiation damage to the crystal. 
Finally, a third dataset was collected on the left side of the crystal with 387×20s 
exposures of 0.5°. A total of 2,029,045 spots were collected, scaled, and merged to 
18,413 unique reflections, equivalent to 94.6% of the theoretical total number of spots 
obtainable (94.1 % in the highest resolution shell). 
 
3.4.2. Structure solving
Images were indexed, scaled and the dataset was merged using DENZO and 
SCALEPACK. The molecular replacement program AMoRe was able to find a 
proper orientation for the search model. We obtained a crystal with one copy in the 
asymmetric unit in a P212121 unit cell, of dimensions 68×76×87Å3.
Refinement of the oriented search model into the final structure was 
performed using the CNS(133) crystallographic suite. The first step of the structure 
solution was to replace the amino acids of the search model (pdb code 1SEQ(130)) by 
their counterpart in HPC-4. The program alignP(120) was used to make a sequence 
alignment which determined the equivalence between the search model and the 
working HPC-4 model residues. In this task, the areas with the most problem were the 
insertions and deletions. Indeed, sometimes it was evident that the sequence 
alignment had placed these in disagreement with the electron density. In this case, the 
density was considered more indicative than the alignment because it contained more 
experimental information even at this early stage. When the density was not clear 
enough to provide a direct answer, some errors in the sequence offset remained for 
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several refinement rounds, until the electron density map became clear enough to 
point out the problem. This occurred for instance in the CDR-H2, where the sequence 
had to be shifted one residue downstream after it became evident that this would 
facilitate the modeling of a proline residue 6 positions away. This correction could 
only be made after 6 rounds of refinements had improved the quality of the map 
enough to perform this modeling task with confidence. Changing the residues of the 
working model for their counterpart in HPC-4 was very useful for the quality of the 
model, and expectedly improved the R factors more than any subsequent rounds of 
building and refinement.  
 An overview of the 
progress of the R factors over 
various refinement stages is 
represented on figure 30. An 
almost steady improvement of 
the R factors is visible in the first 
8 rounds. The short-lived R 
values increases seen in rounds 2, 
3 and 4 (Rfree) or 2 and 3 (Rwork) was due erroneous input files given to the CNS 
program. These turned out to be inconsequential. After 8 rounds of refinements, most 
of the changes that could be done to the model were suggested by the geometry check 
programs WHATCHECK and PROCHECK. It was noticed that in some regions, the 
model had to be distorted away from the electron density to satisfy the canonical 
geometry. As a result, although beneficial in terms of geometric correctness of the 
Figure 30: Evolution of the crystallographic R values 
during refinement. Refinement rounds 8 and 10 were 
performed according to geometric constraints. 
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model, these modifications changed it to a state that did not explain the observed 
intensities as well as did the model without geometric corrections, and R values 
increased. Over the last refinement rounds, the improvements in R values obtained by 
refinement were canceled out by the geometric constraint corrections, and it was 
decided to arrest the refinement process. Final R values of Rwork=20.62 and 
Rfree=27.66 were obtained after 10 rounds of reciprocal space refinement. A summary 
of refinement statistics is shown in table 2. 
 The density for the peptide and for the calcium became visible very early in 
the refinement process, but these were not modeled until round 5. Although placing 
the peptide could in principle have been possible, the proper orientation would have 
been difficult to find in the early maps. Furthermore, this decision has prevented any 
model bias from affecting the density for the peptide. When it became evident that 
additional atoms needed to be positioned in the density to maintain the steady 
Unit cell geometry:            P212121;
a=67.9Å,b=76.3Å,c=87.4Å; 
 = =!=90° 
 
One copy per asymetric unit 
 
Resolution range:              50-2.3 Å 
 
Average signal to noise ratio: I//=14.7 
 
Reflections:                   16,634 used for refinement 
 842 used as test set 
 
Completeness:                  94.6% overall; 
 94.1% in the highest 
 resolution shell 
 
Refinement statistics:         Rwork  =0.21 
 Rfree  =0.28 
 Rmerge =0.11 
 
Bond geometry:                 RMSDlength=0.008Å 
 RMSDangle =1.49° 
Table 2: Summary of refinement statistics. 
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improvement of the R factors, water molecules were placed in the peptide density. 
This way, the sharpness of the peptide density still improved and no bias was taken as 
to the orientation of the peptide. The positioning of the peptide was in large part 
realized by placing the sidechain of arginine 12 in a relatively large protrusion on the 
peptide density. With this constraint, the two possible polarities of the peptide were 
attempted, and only the one with the carboxy terminus nearing the CDR-H3 provided 
a good match to the rest of the density.  The position of the peptide did not explain a 
large portion of density that was visible both on the 2Fo-Fc map and on the positively 
contoured Fo-Fc map, surrounded by negative and partial negative charges. Because 
the relative positions of the electronegative atoms approximately satisfied the classic 
pentagonal bipyramidal geometry, a calcium ion was modeled in this region. By 
modeling in the peptide and calcium, the quality of the map in this region and 
elsewhere improved and R values decreased significantly. 
 In the final model, only 6 residues of the total 536 have their backbone angles 
in generously allowed regions of the Ramachandran plot, and no residues are found in 
the disallowed regions except glycines. Geometric checks carried out on the structure 
reveal that the proline puckering amplitudes and phases are within normal ranges. 
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3.4.3. The structure of HPC-4: general observations
The structure of HPC-4 (fig. 31) is a typical example of the immunoglobulin 
fold. It is constituted of 4 Ig domains, 2 each in the heavy and light chain. The antigen 
binding site is occupied by calcium and by the peptide, as will be described in more 
details in the next paragraph. The ficin cleavage has occurred precisely one residue 
above the heavy-light disulfide bond, and the new carboxy terminal residues of the 
heavy and light chain remain in close proximity. The electron density of the light 
chain ends unambiguously and cleanly after the two C-terminal oxygens of E212, 
suggesting strongly that this is the ficin cleavage site. In the heavy chain, the electron 
density is continuous for the main chain atoms through R213 although weak density 
Figure31: Overall stereo view of the HPC-4 ncFab-Ca2+-epitope peptide complex. 6-sheeted 
regions are represented as arrows. Grey: light chain; yellow: heavy chain; red: CDRs; blue: 
epitope peptide; green sphere: calcium ion. 
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beyond this position leaves ambiguity about the identity of the residue at the C-
terminus. The variable domains of the heavy and light chains each have 9 M strands, 
while the constant domains only have 7. Strands 3c in both the heavy and the light 
chains are very short. The connectivity of the strands satisfies the canonical topology 
in both the variable and constant domains. Each domain possesses a disulfide bond 
linking strands 2 and 6.  
 One of the first features made visible by the 2.3Å resolution level of the 
structure is an extensive network of hydrophobic interactions that maintains the heavy 
and light chains in close proximity despite the absence of a covalent bond. In the 
variable domains, residues P44, L46, F98, and W91 of the light chain and residues I37,
L45, W47, W52, V93, M95, M100 and W103 of the heavy chain constitute a hydrophobic 
core that maintains the two domains in close interaction. In the constant portion of the 
ncFab, the hydrophobic core contains residues F117, V132, F134, and L159 in the light 
chain and L124, L141, F166, P167, and V169 in the heavy chain. The variable and constant 
domains are separated by rather long loops devoid of secondary structure sometimes 
referred to as “elbows”. In the light chain, the elbow runs from K106 to T113, while in 
the heavy chain it runs from V111 to S120. A number of helical portions are found in 
the structure, most noticeably on the C-terminal side of the constant domain of the 
light chain, where the loops connecting strands 1 and 2 and 5 and 6 have more than 
one complete helical turn. Other regions appear helical but their ] and ^ angles do 
not strictly satisfy the definition for helicity.  
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 The G127 to Q131 loop in the C-terminal part of the constant domain of the 
heavy chain has the highest B factor value, and was difficult to model. Atoms of this 
loop were weighed at zero 
during the refinement, but a 
likely conformation was built 
nonetheless in the model. 
Noticeably, this stretch was 
also absent in the phase search 
model, possibly because it is 
highly mobile. Another 
interesting feature found in 
HPC-4 is the presence in the 
first strands of the variable 
domains of a noticeable kink at 
the level of proline 9 (heavy 
chain) or proline 8 (light chain). 
This feature is visible also in 
the phase search model or in Q-425.  
 The packing interactions of the protein molecules in the crystal are relatively 
minor, which suggests that the conformation seen here is relatively close to the 
energy minimum in solution. As seen on figure 32, most of the crystal contacts occur 
on the sides of the molecule. Most interestingly, the antigen and antigen binding 
regions appear almost entirely devoid of any contacts. In the variable portion of the 
Figure 32: Crystal contacts. The structure is represented 
as a van der Waals surface. Red patches indicate atoms 
less than 4Å away from atoms of a neighboring 
molecule. A: orientation with long axis in the plane of 
the sheet, antigen binding site on top and heavy chain on 
the right; B: 180° rotation of A along the vertical axis; 
C: 90° rotation of A along the horizontal axis; D: -90° 
rotation of A along the vertical axis. In C, the 
orientation is such that one looks down into the antigen 
binding site. 
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molecule, only two places are found where backbone atoms are located less than 4Å 
away from a neighboring molecule. The first position is a small patch formed by G44 
in the heavy chain and G100 in the light chain. It is in contact with the carboxy 
terminal residues of the light chain of a neighbor. The second place is the S65G66 
dipeptide on the back sheet of the light chain, which contacts the loops connecting the 
strands 6 to 7 of the constant portion of a neighboring light chain. Importantly, both 
these regions do not diverge noticeably from their equivalent position in the search 
model, even though the packing interactions are very different. This suggests that 
they retained their initial conformation despite being in close proximity to a crystal 
neighbor. 
 An unusual feature of our structure is the presence of no less than 6 cis-
prolines among a total of 26 prolines present in the structure. Although uncommon, 
the presence of cis-prolines is not an anomaly, as this pseudo-imino acid is the only 
residue to which this conformation is not almost energetically entirely forbidden(140).
The 23% representation of cis-prolines seen in our structure is still higher than the 
average 5%(141), but it does not seem unusual considering the 6 and 7 cis-proline 
residues present in the search model or the calcium-dependent antibody Q-425, 
respectively. All cis-proline residues found in HPC-4 have an equivalent cis-proline 
in the search model.  
3.4.4. The antigen and the antigen binding region
One of the earliest recognizable features of the map was the presence of a 
large segment of electron density between the N-terminal portions of the variable 
domains of the heavy and light chains. This density was acknowledged as peptide, as 
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it was in first approximation large enough to contain at least 7 residues. The peptide 
seen in the final structure represents the least model-biased part of the molecule, as it 
was modeled in the latest stages of refinement. Furthermore, no choices were made 
about its orientation until the electron density map acquired a level of detail that 
allowed unambiguous placement of 8 of the 9 residues of the peptide. 
 The detailed description of the antigen peptide that follows mentions two 
numbering schemes. One of them is based on the starting residue of the protein C 
heavy chain. Thus, the first residue of the peptide is actually residue number 8, as it is 
the eighth residue of the heavy chain of protein C. For reference, the scissile bond, 
cleaved by the T-TM complex in the protein C activation reaction, is the peptide bond 
between residues 12 and 13. Peptide residues will be mentioned as the one letter code 
followed by their position on the protein C heavy chain sequence in subscript. A 
different nomenclature relevant to the peptide would be the Schechter and Berger 
numbering scheme(86), applicable when protein C is considered as T-TM substrate. 
This different convention, designated for protease substrates, takes the scissile bond 
as a reference. Residues preceding the scissile bond are referred to as Pn,···, P3, P2 
and P1 (“non primed reigon”), while residues following the scissile bond are referred 
to as P1’, P2’, ···, and Pn’ (“primed region”). In this nomenclature, the scissile bond is 
located between residues P1 and P1’. The two numbering schemes are shown in 
figure 2. 
 The antigen binding groove of the antibody (fig. 33) is mostly formed by the 
CDR-H2, CDR-H3, CDR-L1 and CDR-L3. Although they are not in direct contact 
with the peptide antigen, CDR-H1 and CDR-L2 probably play an important role in 
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maintaining the peptide-contacting CDRs in a shape suitable for high affinity binding 
of the antigen. With the exception of CDR-L3, all CDRs are relatively short, and do 
not protrude significantly towards the groove. As a result, the antigen binding site of 
HPC-4 is relatively deep, and is rimmed by the CDRs. Most of the bottom base of the 
binding site is formed by the elements of secondary structure of the heavy chain. The 
rather deep shape of the groove sets HPC-4 apart from other protein-binding 
antibodies, which are generally characterized by shallow antigen binding sites(142).
The N-terminal aspartic acid of the peptide is not seen in the structure. This is 
most likely because even though the residue is actually present, it is too mobile to 
diffract significantly. The electron density was however sufficiently clear to model 
the following glutamine with confidence. Overall, the peptide adopts a very distinct 
conformation where the residues up to P11 do not have a clearly defined secondary 
structure but where residues R12 to I14 adopt a helical conformation on 5/6 of a turn, 
followed by the carboxy-terminal aspartic acid, which does not belong to the helix.  
 The structure shows an extensive array of interactions taking place between 
the antigen, calcium and the antibody. As mentioned above, the first residue of the 
peptide (D7) is invisible in the current structure, probably because of its high mobility. 
The fact that Q8 is visible is somewhat surprising because no obvious contacts with 
the antibody are found at first. However, by displaying the crystal neighbors it 
becomes evident that the sidechain of this residue is almost within bonding distance 
of the S56 residue of a neighboring light chain molecule (3.92Å). This partial 
interaction likely stabilizes Q8 into place. The great distance between the interacting 
partners results in a rather weak stabilizing effect, as reflected by the high B-value of 
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the glutamine sidechain (in the 60-80 range). Still, it is sufficient to maintain it stable 
enough for X-ray diffraction to occur. The V9 residue is involved in a hydrophobic 
interaction with Y94 in the CDR-L3. The backbone atoms of the rest of the CDR-L3 
constitute a small and rather shallow pocket providing an additional surface feature 
into which V9 is loosely held. The next residue, D10, is maintained tightly in place by 
an ion pair with H50 and a hydrogen bond with W52, both in the heavy chain strand 
immediately preceding the CDR-H2. These strong interactions pull the acidic 
sidechain towards the bottom of the antigen binding groove. The next residue is the 
P11 proline. During the structure determination, a cis-proline isomer was assessed, but 
did not fit the density as well as the regular trans isomer, which was consequently 
Figure 33: Detailed view of the peptide and peptide-binding site. Antibody: solvent-accessible 
surface representation; peptide: sticks representation; calcium: green sphere. Peptide and 
antibody are color-coded according to chemical properties (blue: basic, red: acid, white: 
backbone, orange: hydrophobic, green: uncharged polar). The heavy chain is visible in the upper 
portion of the image, and the light chain is visible in the lower portion. 
95 
adopted. As a result of backbone geometry constraints, the sidechain of this residue is 
pointing towards the solvent cavity. This is a little surprising considering the nonpolar 
character of the proline heterocycle. However, this may result from the geometric 
constraints imposed to the backbone by the surrounding residues. Indeed, R12 is 
tightly maintained in its position by a strong ion pair with D54 of the CDR-H2. In 
addition, this residue is also maintained by a cation-_ interaction between the nitrogen 
atoms of the guanidinium group and the aromatic system of W53 in the CDR-H2. The 
combined strengths of these interactions may compensate for the unfavorable solvent 
exposure of P11. R12 is the first of three residues present in a helical conformation. 
Instead of participating in hydrogen bonding with the nitrogen atom of residue n+4 as 
would classically be seen in an N helix, the carbonyl oxygen of R12 is in chelating 
contact with the calcium ion. This is possible because the corresponding hydrogen 
bond acceptor (which would be D15) does not belong to the helix, thus letting the R12 
carbonyl free and available for interacting with the calcium ion. The upwards 
direction of the carbonyl group is maintained by the next residue, L13, whose 
sidechain is present in a very deep hydrophobic cavity of the antigen binding site. The 
bottom of this cavity is formed by three residues (M95, A100A and M100B) which 
surround the CDR-H3. Two tryptophan residues, W91 in the light chain and W52 in the 
heavy chain, constitute the sides of the hydrophobic pocket which docks L13 into 
place. The downwards position of this leucine is important for calcium binding, as it 
forces the carbonyl oxygen of the previous residue (R12) in an upwards position. The 
next residue, I14, is surprisingly exposed to solvent for a hydrophobic residue. 
Although the hydrophobic residues V9 and P11 in the peptide are in close proximity, 
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the surface offered for binding to the light chain is mostly polar. Indeed, T31 and N92 
are the closest sidechains available. Although the light chain also has the hydrophobic 
residues Y32 and W91 close by, their sidechains are pointing towards the core of the 
protein, and their backbone atoms participate in hydrogen bonding with one shared 
water molecule. Thus, this residue appears to be mostly stabilized by van der Waals 
interactions with the antibody. The last residue of the peptide, D14, is involved in the 
shared binding of calcium together with the CDR-H3 in the antibody. Both its 
carboxylic acid groups (one in the sidechain and one at the carboxy terminus) 
participate in the coordination shell of the ion. Noticeably, D14 does not have a 
binding site on the antibody, as the high density of negative charges present in the 
CDR-H3 would predict. The situation is however very different when the ion is 
present. In this case (seen in the structure), the binding of calcium not only shields the 
peptide from the negative charges of the CDR-H3, but drives the binding event 
through the energy gain offered when completing the full coordination shell of the 
calcium ion. The next section will describe the calcium binding site in more details. 
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 The calcium-binding site has a pentagonal bipyramid geometry (7 
coordination sites), with both the peptide and the antibody heavy chain participating 
in binding (fig. 34). Noticeably, the antibody only binds calcium through atoms of the 
CDR-H3, which provides two carboxylates (D97, D100) and one backbone carbonyl 
(D97). The peptide also provides a carbonyl (R12) and two carboxylates (both the 
sidechain and the carboxy-terminus of D15). The electron density for the ion does not 
appear as an unconnected sphere, but rather as a protrusion connecting the carbonyls 
of R12 in the peptide and of D97 in the CDR-H3. The resulting distances of the oxygen 
atoms with the ion are of 2.63 and 2.70Å, respectively. The pentagon forming the 
base of the bipyramid comprises all three calcium binding CDR-H3 atoms and is 
completed by the two carboxylic acid groups of the peptide. It is not strictly on a 
Figure 34: The calcium binding site. Red backbone: antibody CDR-H3; grey backbone: peptide; 
green sphere: calcium ion; black cross: water molecule. The peptide and the antibody both provide 
3 coordination positions. The top vertex of the coordination shell is occupied by a water molecule.  
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geometric plane, as the carboxy terminal oxygen of the peptide is located about 2Å 
above the other atoms. The bipyramid is completed by the carbonyl of R12 in the 
peptide (bottom vertex), and a water molecule 2.43Å above the calcium ion forming 
the top vertex. The calcium is located almost exactly at the intersection between the 
planes formed by the carboxylic acid functions of D97 and D100 in the antibody and of 
the peptide carboxy terminus. The calcium is noticeably out of the planes of the 
carbonyl functions or of the sidechain carboxylate of D15. To conclude, atoms from 
the antibody, the peptide epitope and a water molecule participate in all possible 
coordination positions of the calcium ion, resulting in slightly distorted pentagonal 
bipyramid geometry. The composition of our calcium binding site is in relative 
agreement with a statistical analysis that we carried out on the 10605 calcium binding 
sites present in the 2006 release of the PDB using an in-house made python program. 
In this analysis, it was found that the “average” calcium binding site contains 2.9 
oxygen atoms from carboxylic acid functions (glutamic acid or aspartic acid), 0.77 
oxygen atom from water molecules, 2.89 backbone carbonyl oxygen atoms, 0.34 
asparagine side chain oxygen atom and 0.06 rare binders like threonine or glutamine 
side chain oxygen atoms. The calcium binding site seen in the present structure has a 
slight overrepresentation of carboxylate oxygens (4 instead of about 3 in average), 
and a slight underrepresentation in backbone carbonyl oxygens (2 instead of about 3 
in average). The presence of a single water molecule is in good agreement with the 
average 0.77. When considering that the carboxylate oxygen is probably replaced by 
a carbonyl oxygen in GDPC (see discussion), then the calcium binding site has a 
canonical composition. 
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4.1. Packing environment 
 
Except in a few cases (notably insulin, oxidases in the peroxisome, or 
hemoglobin in the hemoglobin C disease, as reviewed elsewhere(143)), proteins rarely 
form crystal packing interactions in their biological context. As a consequence, it is 
important to assess whether the conformation observed in a crystal structure is 
affected by crystal contacts or not. Although in principle the physiologic 
conformation may well pack readily into a crystalline lattice, it is of importance in 
any crystal structure endeavor to assess the effect of crystal packing on the natural 
conformation of the protein and hence on the interpretation of its function. Apart from 
their contributions to crystal formation, packing interactions can be detrimental to 
structural studies because they are capable of distorting flexible loops into non-
physiologic conformations. Although in most instances, the structures obtained by X-
ray crystallography are compatible with results from techniques operating in solution 
(essentially NMR or other spectroscopic methods), the validity of a crystal structure 
always needs to be assessed.  
 To address packing environment, the interactions with the solvent that occur 
in the crystalline phase can be considered. As a first approximation, the Matthews 
coefficient(144) VM can be used to that effect. It is a measure of the “protein density” 
inside the crystal, and indirectly provides information on its solvent content. It is 
analogous to a partial specific volume, and is expressed in Å3/Da. Usual values of VM
are between 1.5Å3/Da for densely packed crystals and 4.0Å3/Da or more for loosely 
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packed crystals. In our case, the Matthews coefficient was of 2.4Å3/Da, a value well 
within normal ranges of packing density. A recent statistical analysis of the 
distribution of Matthews coefficients in the PDB elegantly demonstrated a correlation 
between densely packed crystals and diffraction to higher resolutions(145). Evidently 
both high resolution and limited packing interactions are desirable, but this statistical 
trend indicates that these goals are most often incompatible. In our case, the 
resolution of 2.3Å seems to be in a good agreement with this correlation, as VM in the 
order of 2.2-2.8Å3/Da were found to be the most frequent in structures with 
resolutions comprised between 2.01 and 2.40Å (average 2.6Å3/Da). Still, although it 
is a good indicator of the tightness of the crystal packing, the solvent content of a 
protein is not a direct indicator of the nature of the crystal contacts. By examining the 
crystal structure it is possible to characterize which surfaces of the protein participate 
in packing interactions. 
 As seen in figure 32, most of the crystal contacts in our structure appear on the 
sides of the molecule, with little packing interaction occurring at the antigen. The 
distance threshold used on this figure was set at 4Å, a value confidently greater than 
typical noncovalent bond distances to ensure that the areas that appear free of contact 
really are at appreciable distance from the next crystal neighbor. The antigen is 
surrounded by a consequent solvent channel, with only the second residue of the 
peptide participating in a weak ionic pair with a neighboring molecule. The fact that 
the first residue in the peptide is invisible in the structure, together with the high B-
factors of the second residue indicate that these residues are very mobile, and that the 
observed crystalline contact may actually be rather transient. In our case, the mere 
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presence of calcium and peptide in the antigen binding site is a good indication that 
the potential distortions introduced by the crystallization are not significant enough to 
disrupt the function of the protein. Hence it is reasonable to think that our structure is 
similar to the one that would be observed in solution.  
 4.2. On the structure of the protein C zymogen 
 
Crystallization of GDPC in complex with HPC-4 and calcium was attempted 
during this project, but unfortunately without success despite the large number of 
trials. Consequently, the structure we obtained provides only a limited amount of 
information on the conformation of the activation region of GDPC in the zymogen 
form. In this section, the conformation of the epitope peptide and its relevance to the 
structure of zymogen protein C will be discussed.  
 Although the sequence of a protein is the most important determinant of its 
structure, the inherent flexibility of polypeptide chains tends to make them adopt a 
range of conformations around one or more energy minima. This plasticity is often 
functionally important for instance in enzyme mechanisms, where conformational 
changes can sometimes be of significance in the catalytic cycle(146). Other 
determinants of protein structure include pH or other solvent characteristics, 
temperature, and most importantly binding of effector molecules or ions, or structural 
environment. Concerning our structure, these considerations have important 
implications in terms of the validity of the zymogen protein C peptide conformation 
that is seen. The interaction with HPC-4 may stabilize the peptide into a conformation 
that would not be seen otherwise in solution. By the same reasoning, there is a priori 
no indication that the conformation adopted when binding to HPC-4 is similar to the 
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conformation of the catalytic complex within the active site of thrombin in the T-TM 
activation reaction. 
 Still, the calcium dependence of the binding event and the ability of the 
protein C peptide to directly bind calcium are somewhat intriguing in this context. It 
is tempting to propose the hypothesis that the conformation seen in complex with 
HPC-4 is one and the same with the conformation adopted in the active site of the T-
TM complex. One may then propose a model in which a calcium binding site is 
located in the zymogen protein C at the interface between the activation region and 
the calcium binding loop. In this model, the coordination positions provided by the 
activation region would be those seen in the HPC-4 structure, where the P1 arginine 
and the P3’ aspartic acid provide oxygen atoms for chelation. The most compelling 
argument in favor of this otherwise fragile hypothesis comes from a mutagenesis 
study of protein C. In this particular study, the acidic residues in P3 and P3’ were 
mutated to glycines, and about a third of the calcium affinity was lost(39). The loss of 
affinity would be in agreement with the hypothesis where calcium is bound directly 
by P3’ as seen in our structure. Furthermore, shared calcium binding would also 
provide a likely mechanism for the conformational interplay occurring in between the 
two regions during calcium titration experiments, for which there is extensive 
evidence. For instance, the intrinsic fluorescence change observed by titrating protein 
C with calcium is lost upon activation, and the introduction of fluorescent reporters in 
the activation region have a dramatic impact on the fluorescence response to calcium 
titration(14). Furthermore, modeling studies did not rule out the possibility of a direct 
interaction taking place between the calcium binding loop and the activation region in 
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the zymogen form of protein C(40). The basic residues in the calcium binding loop of 
protein C have been proposed to interact with thrombomodulin(26) leaving the acids in 
P3 and P3’ available for ionic interaction. However, several observations raise 
questions about this candidate mechanism.  
 First and foremost, this hypothesis is hardly compatible with biochemical 
evidence. HPC-4 was initially studied for its ability to bind protein C(41). If the 
hypothesis previously described were true, then there would be a steric clash between 
the GDPC calcium binding loop and the CDR-H3 of HPC-4 during the binding event, 
which would result in a dramatic conformational change of PC. Although not 
formally impossible, this is quite unlikely. Furthermore, the helical conformation seen 
in the structure would not be expected to be a good substrate to the T-TM complex. 
The helical conformation in itself is not unusual for a thrombin substrate, as 
evidenced by the thrombin structure in complex with fibrinogen (pdb code 1BBR(147)), 
in which a short helical segment is found 6 residues N-term from the scissile bond. It 
is rather the position of the helical segment, C-term from the scissile bond, which 
would make this conformation an unlikely fit in the active site of thrombin. 
Furthermore, thrombin substrates usually adopt a rather extended conformation. A 
second problem with this model is that extensive evidence across many coagulation 
factors argues that the calcium binding loop does not require additional coordinating 
atoms provided by a different loop in order to bind calcium with high affinity. In fact 
the shared binding of calcium by the activation region would rather be suboptimal 
compared to binding to the calcium binding loop alone, which has all coordination 
positions necessary. Finally, if the calcium binding mode seen in the HPC-4-peptide 
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structure has any relevance to the conformation of the zymogen, then there should be 
a resemblance between the CDR-H3 of HPC-4 and the calcium binding loop of 
protein C. However, these two loops are very different. The calcium binding loop of 
protein C is 10 residues long, and its first and last residues participate in the binding. 
In contrast, the CDR-H3 of HPC-4 only contains three residues, and calcium binding 
residues are only separated by two residues. Consequently, the protein C residues 
which bind calcium in the HPC-4 structure are unlikely to do so in the zymogen 
protein C in solution or in complex with T-TM. 
 This raises a question about the hypothetical structure of PC when in complex 
with HPC-4. Although we need to consider the possibility that the peptide 
conformation that we observe may not be the same as the one followed in the protein 
C-HPC-4 complex, several considerations argue otherwise. First, the activation region 
is known to be fairly flexible, a condition necessary for its recognition by the rather 
deep groove of the active site of thrombin. This flexibility can also be invoked to 
argue that even in the structural background of PC, there are still enough degrees of 
freedom in the epitope to allow it to adopt the conformation seen in our structure. 
Furthermore, the alternate case appears quite unlikely. Indeed, it would amount to 
HPC-4 having developed an antigen binding site able to recognize two different 
conformations of the same antigen, both in a calcium dependent fashion. This is 
highly unlikely considering the scarcity of antibodies having a calcium binding site. 
Regarding the calcium binding, one could argue that the carboxylic acid present at the 
terminus of the peptide is absent from PC, and hence that the conformation of the 
peptide is necessary different. However, the carboxy terminus would be replaced in 
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PC by a backbone carbonyl. The corresponding oxygen, although less electronegative 
than the one of a carboxy terminus, is still partially charged because of the resonant 
property of the peptide bond. The enhanced structural rigidity of a polypeptide 
backbone over a carboxy terminus could compensate for this less than optimal 
chemical function. Noticeably, the replacement of the carboxy terminus by a carbonyl 
would constitute a more usual composition for the calcium binding site, with 3 acidic 
oxygens, 3 carbonyl oxygens and one water molecule. Incidentally, the present 
position of the carboxy terminus would orient the next two residues of PC in a 
position which does not overlap with any antibody atom, consistent with the absence 
of binding of the D15-Q27 peptide(41). The same is true for the N-terminus of the 
peptide, which points away from the antibody in a direction where the PC protease 
domain would not clash with the antibody. 
 
4.3. Correlation with fluorescence results 
 
The fluorescent properties of tryptophan are to some extent changed by 
polarity variations in its immediate chemical environment. Fluorescence changes in 
the spectral region of maximal emission for tryptophan were observed in the ncFab in 
the presence of calcium and epitope peptide. In the absence of structural information, 
it is often difficult to infer the nature of the changes that occur in the vicinity of the 
reporter residues, but the structure we obtained allows some hypotheses. Two 
mechanisms seem most likely in our case. First, the fluorescence change could 
directly report the binding of calcium in the immediate vicinity of one or more 
tryptophan residues. The presence of a positive electrostatic charge would likely 
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modify the electronic system of the aromatic rings of tryptophan, causing the 
fluorescence change. The other possibility would be that binding of calcium and 
peptide transmit conformational changes to one or more tryptophan residues, causing 
the polarity of their immediate environment to change, and inducing their increased 
fluorescence response. These two mechanisms are not mutually exclusive, and are not 
the only ways to explain the observed fluorescence change. Our structure represents 
the endpoint of the structural transition initiated by the binding of calcium and 
peptide. Hence, only assumptions can be made as to the nature of the structural 
changes responsible for the fluorescence change.  
 Several tryptophan residues appear in direct contact with the peptide. At the 
bottom of the combining site, W91 (light chain) and W52 (heavy chain) most likely see 
their environment change upon calcium and peptide binding, either through 
hydrophobic interaction for W91 or through ionic interaction for W52. The electronic 
system of W53 is also most likely affected by the cation-_ interaction that occurs with 
the ` nitrogen of R12 in the bound peptide. The fluorescence response observed for 
HPC-4 ncFab upon calcium and epitope peptide binding can thus be rationalized 
without any kind of conformational rearrangement to the combining site. As will be 
discussed in the next section however, such conformational changes are likely to 
occur, and could in principle participate to the fluorescence response described above. 
In particular, the ion pair between R12 in the peptide and D54 in the CDR-H2 likely 
pulls the backbone in a motion that could transmit to the two preceding tryptophan 
residues W53 and W52. This effect does not directly require the presence of calcium, 
and could explain the mild response obtained when titrating the peptide in the 
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absence of the ion(41). The weak fluorescence response we observed in the absence of 
peptide, which was reported also for HPC-4, can be explained with the present 
structure. Indeed, the antibody and the water alone account for most of the 
coordination positions used to bind calcium. The possible conformational changes 
occurring when calcium binds to the CDR-H3 would transmit to tryptophan W52,
transmitted through M95. The movement of CDR-H3 would also likely affect the 
tryptophans W52 and W53 of the CDR-H2 by conjugated movements transmitted 
through the intercalated CDR-H1 loop. Such a concerted movement of CDR loops 
would not be without precedent(49).
The reversal of the fluorescence intensity effect that was observed at the 
highest peptide concentration (fig. 21) can also be tentatively addressed with our 
structure. Although only the peptide-HPC-4 complex has a full calcium binding site, 
the peptide still participates in 3 coordination positions, which amounts to as many 
positions as the antibody provides. The calcium could thus in principle bind to the 
peptide alone, although with a lower affinity. By increasing the peptide concentration, 
one could then compensate the low affinity of the half calcium binding site on the 
peptide, and to start having significant binding nonetheless. This would scavenge the 
ion away from the antibody, which is the only molecule providing a measurable 
fluorescent signal. This would then explain why the fluorescence gain decreases at 
high peptide concentration. Also, it is seen that the full calcium binding site is 
completed by a D-X1-X2-D motif in the antibody (where X1 is D98 and X2 is Y99). 
Coincidentally, the first four residues of the peptide used in our fluorescence studies 
also satisfy this motif, with two aspartic acid present two residues apart (D7-Q8-V9-
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D10). It is thus possible to invoke a model in which calcium would mediate the 
dimerization of the peptide. In this model, one peptide would adopt the conformation 
seen in the antigen, and the second would form a complete calcium binding site by 
having its amino terminal segment mimic the CDR-H3 conformation of the antibody. 
The presence of additional binding sites in the peptide-HPC-4 interaction would 
explain the higher affinity for calcium of this complex compared to the hypothetical 
peptide dimer. The absence of fluorescent reporter residues in the peptide makes this 
hypothesis difficult to test. 
 
4.4. Hypotheses about the mechanism of the switch 
 
The mechanism of the conformational switch occurring during HPC-4 binding 
can only be determined by comparing our structure with the structure of HPC-4 in the 
absence of ligands. At the time of composition, crystals of the ncFab had been grown 
in 5mM EDTA, which diffracted below 2.25Å without any kind of optimization, but 
were too twinned to provide a dataset. This result is very promising, and may result in 
a second structure that will be used to test the following hypotheses.  
 Examination of the distances between charged or partially charged oxygen 
atoms in the calcium binding site reveal that they are significantly shorter than 
anywhere else in the protein. By generating a sorted list of the interatomic distances 
between charged oxygens in the whole structure, it appears that 10 out of the 15 pairs 
found below 4.5Å are clustered in the calcium binding site (the average distance 
being 36Å). The four shortest distances are also found there, with the exception of the 
distance between E79 and E81 in the light chain, which is maintained by the proximity 
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of the positive charge of R61. This finding, in addition to the established fact that ionic 
interactions occur between the positive charges of calcium and the negative charges 
of the carboxylates, indicates that the ion is responsible for these abnormally short 
distances. The removal of calcium and peptide would thus result in many negative 
charges in close proximity to one another. A reasonable expectation is that ionic 
repulsion is going to take place and will result in the adoption of greater distances 
between charged oxygens, to conform to more typical distances as seen elsewhere in 
the structure. Although some of the movement could be accommodated by mere 
sidechain rotations, backbone rearrangements could be involved as well. Especially, 
the CDR-H3 conformation seen in the present structure has a pronounced backbone 
kink in the Y99-D100 dipeptide, which is resolved into the next strand by a short helical 
segment. As a consequence, the CDR-H3 is almost contained in a plane orthogonal to 
the one formed by strands 6 and 7. This backbone kink is energetically unfavorable, 
but is probably maintained nonetheless because of the calcium binding enthalpy gain. 
However in the absence of the ion, this conformation would be expected to be shifted, 
driven by electrostatic repulsion, in the looser conformation usually seen for CDRs, 
where the loop is approximately in the same plane as the sheet from which it 
protrudes. With such a short segment between strands, one might even expect to see a 
canonical M-M hairpin at this location.  
 The presence of the negative charge cluster seen in the complex has 
consequences on the possible mechanism of the binding event. Indeed, it indicates 
that binding of the peptide to the antigen in the absence of calcium is confronted with 
a high energy barrier caused by electrostatic repulsion. If at all even possible (as 
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slight fluorescence changes might indicate), this event would be expected to be 
unlikely. On the other hand, binding of calcium to the antibody alone does not face 
any foreseeable energy barriers other than the displacement of whichever positive 
charge currently neutralizes the acidic functions of the CDR-H3 (in all likeliness a 
sodium ion from the buffer). Unlike binding of the peptide alone, binding of calcium 
alone would thus be expected to be more favorable. The Ca2+-HPC-4 complex would 
then readily bind the peptide because the negative charges of the antibody would be 
shielded, and because of the energy contribution incurred by completing the 
coordination shell of calcium. This mechanism is consistent with the characteristic 
sharpness of the elution peaks obtained on the epitope affinity chromatography (see 
figs. 18 and 19). In this column, elution is performed by replacing calcium by EDTA 
in the running buffer. The removal of calcium from the ternary complex then 
transforms the high affinity binding occurring throughout the peptide into a strong 
ionic repulsive interaction occurring at the carboxy terminal helix, poorly 
compensated by the remaining binding sites of the median part of the peptide. 
 
4.5. On the affinity of the peptide-Ca2+-HPC-4 
interaction 
 
One of the most striking features of the antigen binding site of HPC-4 is the 
great number of ionic interactions. Besides the ionic character of calcium binding, 
two additional ion pairs are found. This observation contrasts with the classical view 
of antigen binding sites, in which interactions are dominated by van der  Waals 
contacts and hydrogen bonds(52). Ionic interactions figure among the most stable 
noncovalent interactions, so their presence may be of functional significance. The 
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activation region of blood coagulation serine proteases is known to be very mobile, 
based on the high B-factor values observed in this region of factor VII(148) and of the 
prethrombin-2 structure(149). This flexibility in protein C is accommodated by 
thrombin through ion pairing with R15 and M-sheet hydrogen bonding between the 
active site and the substrate. In HPC-4 however, the fact that all but one charged 
group of the epitope are faced with an opposite charge in HPC-4 may be a mechanism 
by which the antibody accommodates the flexibility of the antigen. Noticeably, the 
R15 sidechain central to the peptide is found to be in an ion pair both in the interaction 
with HPC-4 and with thrombin, where the residue D189 pulls and maintains it deep 
within the active site.  
 These considerations must however be put into perspective especially 
regarding the stability of the complex to high salt concentrations. During the course 
of the project, an experiment was done in which ncFab fragments in complex with the 
epitope peptide were exposed to 2M salt (see section #3.1.2., fig. 18). This 
experiment was performed in an attempt to selectively detach ncFab or Fab from the 
peptide affinity column in order to separate them. It was not a good method for the 
intended goal (both fragments were equally retained), but it still demonstrated that the 
interaction can withstand very high salt concentrations. If ionic interactions were 
important for affinity, one would expect high salt concentrations to be disruptive by 
virtue of competition of the interacting charges with the sodium and chloride ions 
present in solution. The resistance of the interaction to high salt can be rationalized by 
the structure of the complex and by considering the underlying electrostatic attraction. 
This force is governed by Coulomb’s law, which states that it is inversely 
112 
proportional to the permittivity of the medium in which the charges are located. The 
degree of solvent exposure would be expected to affect the local permittivity, and 
consequently the force of interaction of a given ion pair. In the structure, it can be 
seen that most ion pairs are located relatively deep in the binding site, where the 
nonpolar environment would strengthen the interaction. This location towards the 
central core of the structure would also prevent the ions in the solution from 
penetrating merely because of their size, which would decrease their effective 
diffusivity in the vicinity of the ion pair and thus their ability to disrupt it. The 
enhancement of hydrophobic interactions that is obtained when increasing the salt 
concentration must also be considered. Thus, the absence of dissociation at high salt 
indicates that the increase in hydrophobic interaction strength is able to compensate 
for the relative weakening of ionic interactions.  
 In the same setting, the fragments were submitted to 2M salt in the presence 
of 0.5M guanidine, a potent chaotrope agent. The fragments did not detach either, in 
agreement with the absence of hydrogen bonds seen in the structure. 
 The behavior of the complex in high salt is also interesting to analyze in terms 
of calcium binding. The high concentration of sodium ions present in the wash 
solution might be expected to disrupt the calcium binding by neutralizing the negative 
charges of the carboxylates. The failure of sodium to compete calcium out of the 
ternary complex could be attributed to the suboptimal coordination geometry offered 
by the calcium binding site to sodium. It could also indicate that a fully occupied 
calcium binding site is to some extent more favorable energetically than the sodium 
salt form of the separated species. This emphasizes the importance of calcium binding 
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not only as an electrostatic shield to the repulsion between peptide and antibody, but 
also as an important energetic contribution through the completion of a full 
coordination shell.  
 The retention of the fragments that was obtained in low salt and even in low 
salt plus 30% ethanol must also be analyzed. Indeed, the previous result obtained in 
high salt indicated that hydrophobic interactions have an important contribution to the 
binding strength. By decreasing the polarity of the solvent, hydrophobic interactions 
are supposed to weaken, yet 0.01M NaCl or even 0.01M NaCl with 30% ethanol were 
not sufficient to achieve dissociation in the above series of experiments. Thus, these 
particular ion pairings can compensate the loss or decrease of hydrophobic interaction 
caused by the combined effects of a 200× reduction in salt concentration and 30% 
ethanol.  
 Taken together, these data indicate that the binding strength of the peptide to 
HPC-4 is contributed both by hydrophobic interactions and by ionic interactions. In 
addition, calcium provides significant contributions both through ionic shielding and 
through completion of a full coordination shell. The interacting partners identified at 
the molecular level in the structure are in agreement with the macroscopic effects 
seen in affinity chromatography results. 
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 4.6. Comparison with Q-425 
 
HPC-4 was the first antibody with a characterized calcium binding site, and 
the present work provides a basis for comparison with the only other example of a 
structurally solved calcium dependent antibody(48). The extent of the comparison is, 
however, limited by the composition of the complexes. In the case of Q-425, the 
structure is available in the presence or absence of calcium, but not for the ternary 
complex whereas in our case, the structure of the ternary complex is the only one 
currently available. This will no longer be true in the near future, as we were able to 
grow diffracting crystals of the ncFab in the absence of calcium or peptide which will 
soon yield the structure of the unliganded form of the HPC-4 ncFab. 
 The antigen binding sites of HPC-4 and Q-425 are appreciably different in the 
path adopted by the backbone of the CDRs and especially in CDR-H3. In our 
structure, this CDR forms the rim of the binding site, and is kinked away from the 
groove. In Q-425, the CDR has one more residue, and the resulting loop forms the 
Figure 35: Overlay of HPC-4 with Q-425 (pdb code 2ADJ). Left pane: overview of the variable 
domains of both antibodies. Q-425 is represented in black; HPC-4 is represented with the same 
color coding as in fig. 31. Right  pane: close-up view of the CDR-H3. In Q-425, CDR-H3 
protrudes towards the antigen binding site, whereas in HPC-4, it is kinked backwards and away 
from the antigen. The alignment rms is 0.938Å. The calcium in Q-425 (black sphere) is located 
4.77Å from the calcium in HPC-4. 
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bottom base of the combining site by protruding forward into the antigen binding 
groove. It extends so far that it comes in direct contact with the CDR-H2 and by 
doing so prevents the access of the CDR-H1 to the binding site. In HPC-4, the CDR-
H1 contributes to the rim of the antigen binding site but does not directly interact with 
the antigen. It is however in close contact with W53 in the CDR-H2 and D97 in the 
CDR-H3, which are direct antigen ligands. 
 More importantly, the two antibodies seem to differ by the mechanisms 
underlying their calcium dependence. Surface plasmon resonance and structural 
studies demonstrated that the increase in antigen affinity occurring upon calcium 
binding to Q-425 arises only from minor structural rearrangements. In this case, the 
effect of calcium on affinity is thus merely limited to the completion of the 
coordination shell. This absence of conformational rearrangement can be attributed to 
the presence of only 2 charged oxygen atoms in the surroundings of the calcium ion. 
In the ion-bound structure, these atoms are located 2.49Å apart, and they shift to 
3.10Å in the calcium-free form without involving important backbone 
rearrangements. In the case of HPC-4 discussed earlier, in addition to the bridging 
mechanism seen in the structure, it is believed that binding of calcium to the antibody 
is inducing conformational rearrangements. Thus in Q-425, the ion strictly acts as a 
bridge between antigen and antibody, whereas in HPC-4 the ion has the additional 
effect of shaping the antigen binding site into a high affinity conformation. 
 In the report of the Q-425 structure, the authors attributed the scarcity of 
calcium-dependent antibodies seen in the PDB to some selective disadvantage of this 
particular mode of antigen binding. The increased rigidity of the antigen binding site 
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conferred by calcium binding and the multicoordinated nature of the binding were 
proposed as detrimental. This reasoning is based on the assumption that the structures 
available in the PDB represent an accurate depiction of the variety of binding modes 
that exist naturally, which may or may not be the case considering the many millions 
of antibodies present in a typical immune system(150), or the estimated ~1.7×108
different combinations potentially accessible by the combinatorial effects of V(D)J 
recombination, somatic hypermutation, and class switching(59). The requirement for 
calcium was also proposed to be favorable only through the increased binding energy 
for antigens with limited surface available for binding such as the heavily 
glycosylated Q-425 antigen CD-4. Why the glycosylated surfaces would be 
unavailable for typical antigen interaction remains unclear, since there are examples 
of carbohydrate specific antibodies for instance in allergies(151) or in heparin-induced 
thrombocytopenia(152) to name a few. Still, this would be in relative agreement for 
HPC-4, where the binding strength of calcium is taken advantage of to accommodate 
the unusual flexibility of the antigen.  
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We have solved the 2.3Å structure of the calcium-dependent antibody HPC-4 
ncFab in complex with calcium and the epitope peptide. The structure reveals a 
singular and unprecedented binding mode for calcium. In contrast with the only other 
known structure of a calcium-binding antibody, the calcium ion is believed to induce 
profound conformational changes to a region of the backbone of HPC-4, in addition 
to its more conventional role as a bridge between antibody and antigen. Thus, our 
findings represent an important step forward in the understanding of the structural 
biology of metalloproteins in general and immunoglobulins in particular.  
 Together with the initial biochemical characterizations of HPC-4, the present 
work provides a solid experimental framework which could form the base of many 
additional studies. As announced earlier, a diffracting crystal of the ncFab grown in 
the absence of peptide or calcium was obtained, and diffracted to promising 
resolutions. This will likely yield a second structure in the near future. In the 
meantime, the structural rearrangements occurring upon calcium and peptide binding 
that we postulated based on our structure represent testable hypotheses that could in 
principle be addressed using nuclear magnetic resonance spectroscopy techniques. In 
addition, the different residues involved in the particularities of HPC-4 identified in 
our structure could be modified through selective mutagenesis in order to better 
dissect their relative contributions to the overall function of HPC-4.  
 The calcium dependence of this antibody has a strong potential also in terms 
of bioseparations and biosensing. In these fields, the high affinity of antibodies 
5. CONCLUSION
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generally prevents them from being used because the conditions required to dissociate 
the antigen of interest (for instance a therapeutic agent in bioseparations or a 
measured analyte in biosensing) are often incompatible with operation requirements. 
Thus, the ability to rationally design antibodies with reversible binding properties 
represents an important future milestone. Our structure provides a solid foundation 
which can readily be used to that effect. 
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X.1. Characterization of macroseeding-assisted 
crystal growth 
 
The aim of this appendix is to find constants able 
to characterize the growth of the crystals. Experimental 
crystal volumes measured over time are used to validate a 
mathematical growth model. The experimental dataset 
that is used was obtained by averaging the volume of 6 
crystals measured daily during macroseeding (see fig. 
28). 
 The crystals were parallelepipeds with a cuboid geometry (see fig. X.1.1.). 
Their dimensions were measured using the microscope, and their volume was logged. 
It soon became apparent that the ratio m between their longest dimension and their 
shortest dimension did not vary over time, with an average value of 13.77. The length 
of the small square sides, x, can thus be used as a characteristic dimension of the 
crystals. Also at any time t, the volume V(t) of a crystal is obtained by: 
 
[X.1.1.]    [ ]3)()( txmtV =
Similarly, the area A(t) available for growth is easily obtained from the geometry as  
 
[X.1.2.]  ( ) 222 )(42)(4)(2)( txmtxmtxtA +=+=
APPENDICES
Figure X.1.1: Geometry of 
the ncFab-Ca2+-peptide 
crystals. 
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Crystals grow by addition of protein copies on to the surface of a nucleus. It is why 
many crystal growth models assume that the growth itself is directly proportional to 
the area of the crystal(106). In this line of thinking, we will model the evolution of the 
crystal volume as follows: 
 
[X.1.3.]    )(tAK
dt
dV
=
where K (units: µm·day-1) is a “macroseeding growth constant” we seek to determine. 
This model is a simplification of more complex equations which take into account the 
protein supersaturation in the growth medium. In our case, the protein concentration 
in the drops will decrease upon addition of the molecules onto the crystal. However it 
is regularly brought back to its initial value by the macroseeding procedure. Indeed, 
macroseeding consists of repeatedly placing the crystals in a fresh drop of known 
composition. It will thus be assumed that the protein concentration (and thus the 
supersaturation) is constant over several macroseeding cycles. In our expression, the 
constant K encompasses supersaturation, diffusion of the protein molecules to the 
surfaces of the nuclei and kinetics of adsorption as well as possibly other 
undetermined factors.  
 To derive an expression for V(t), one needs to replace both terms of the 
previous equation so that there is only one value varying over time. The characteristic 
length x(t) seems most appropriate: 
 
[X.1.4.]  [ ] ( )[ ]23 )(42)( txmKtxm
dt
d
+=
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Rearranging this expression yields the following differential equation: 
 
[X.1.5.]   ( ) 2
3
)(42 tx
m
mK
dt
dx +
=
Solving this equation provides us with an expression for the characteristic length as a 
function of time: 
 
[X.1.6.]   ( ) cstt
m
mKtx +

+
=
3
42)(
The integration constant cst can be equaled to zero by considering the initial 
condition of a size of zero at the beginning of the experiment. The previous equation 
then becomes: 
 
[X.1.7.]   ( ) t
m
mKtx

+
=
3
42)(
The experimental data was an average volume, so we can use [X.1.1.] to derive our 
growth model: 
 
[X.1.8.]  [ ] ( )
3
3
3
42)()( 




+
== t
m
mKmtxmtV
After simplification, the final expression for the time dependence of macroseeded 
crystal volume is obtained: 
 
[X.1.9.]   
( ) 3
2
3
3
27
42)( t
m
mKtV 









+
=
Interestingly, the volume shows a cubic dependency on time. Because the numerical 
value for m was determined experimentally (m=13.77, bracketed term=36.33), there 
is only one parameter (K3) to this model. A simple way to determine K is to notice 
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that the model can be linearized by applying a cubic root operation on the expression 
for growth: 
 
[X.1.10.]   
( ) t
m
mKtV 




+
= 3/2
3
3
42)(
The resulting relationship shows that the cubic root of the volume is in a direct linear 
relationship with time, where the slope is the product of the bracketed term and of the 
constant of interest, K. The value of the slope is found using a linear regression: 
y = 20.154x
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As seen on the graph, this model provides a remarkable correlation to the data 
(R2=0.983) with a slope of 20.154. The numerical value for K is found to be: 
 
( ) 1
3/2
3/2 1.6
77.133
77.1342
154.20
3
42 =
×
×+
=




+
= daym
m
mslopeK µ
The macroseeding growth rate is thus found to be K=6.1µm·day-1. The following 
graph shows the quality of the fit in terms of volume. 
133 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
0 1 2 3 4 5 6 7
time (days)
Vo
lu
m
e
(×
10
^6
µm
^3
)
As seen on this graph, the latest volume is smaller than the one predicted by the 
model. In practice, it was often seen that sprouting would slow down the growth of 
the seeds. One could then modify the model by introducing a growth constant that 
decays over time. However, most of the monotonously decaying functions by which 
one could multiply the constant K would ultimately offset the cubic growth of the 
crystal, resulting in a size decrease. This is not what was seen in reality, where 
crystals would slowly stop growing but never decreased after the maximal size was 
reached. A different term that can be modified in the model to account for the 
decrease in growth rate would be the cubic exponent itself. Multiplying the exponent 
by a function that converges towards 0 would result in a smooth transition from cubic 
growth (V÷cst·t3) to an arrested growth phase (V÷ cst·t0=cst). In physical terms, the 
decay of the exponent could tentatively be explained as the gradual disappearing of 
the number of dimensions available for growth due to sprouting. Exponential 
functions are classically seen in many physical phenomena where it is often used to 
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model decays. In our case, we propose the following, “decaying exponent”, modified 
model: 
 
[X.1.11]  
( ) )/exp(3
2
3
3
27
42)( tt
m
mKtV 




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



+
=
The additional constant V would be a “decay time” (units: days) to determine. In the 
early time points, the exponent term would approximate 3·e0=3, and the growth 
would be cubic with respect to time, just as in the initial model. Then at later time 
points, the exponential terms would start converging towards 0, resulting in growth 
arrest. Using the same dataset and a nonlinear fitting procedure, K and V values of 
6.8µm·day-1 and 70 days are obtained, respectively. The average residuals of each 
model compared to the dataset can be used to compare their goodness of fit. The 
regular model has an average residual value of 79×103µm3, whereas the decaying 
exponent model has an average residual value of 49×103µm3. The introduction of the 
decay time, V into the derived model allows to substantially improve the fit, mostly by 
better accounting for the slowing down of growth that occurs at our last time point. 
The two models are plotted on the following graph.  
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 X.2. Cryoprotection 
 
At first, the cryoprotectant concentration C in the drop of volume V is zero. A small 
volume v is then removed, and replaced by the same volume of cryoprotecting 
solution of concentration Cf, so that the volume is maintained at V. Thus, at the end of 
the first step (step number n=1), the concentration in the drop is  
[X.2.1.]    
V
Cv
C fn

==1
After the second step, a volume v of the drop (presently at concentration C1) will be 
replaced by a volume v at the concentration Cf. Thus, the concentration at the end of 
the second step, C2, will be: 
[X.2.2.]   
( )
V
CvCvV
C f
+
= 12
To find the iterative formula, one can replace C1 in the precedent equation by its 
literal expression, yielding: 
[X.2.3.]   
( )
V
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C
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Factoring (X.1.3.) with the expression for C1 yields: 
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Pursuing this for greater values of n yields: 
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[X.2.5.] can then be rewritten in a more compact form: 
 
[X.2.6.]    
 
This expression is generally identified as a Taylor series in (V-v)/V, and since by 
construction -1<(V-v)/V <1, it also satisfies the definition for a MacLaurin series. 
This formalism is interesting to examine the behavior of Cn at high values of n, where 
the following MacLaurin identity is valid: 
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So for a great enough number of solution replacements, equation [X.2.6.] will 
collapse to the equality Cn=Cf, clearly demonstrating the convergence of the [X.2.6.] 
series. In other words, by repeating the exchange step for enough number of times, it 
is possible to asymptotically reach the final concentration Cf. This could be expected 
with no derivation but the precise number of steps required to arrive at a value of Cn
that is significantly close to Cf can only be determined using [X.2.6.]. Even though it 
is not easily amenable to analytical solution (because of the sum form), relevant 
values can be found by plotting [X.2.6.] for various n and v values that are technically 
feasible (Cf and V being otherwise dictated by the required cryoprotecting 
concentration and the evaporation rate, respectively). The following plot was realized 
for 5 different values of v: 
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Using the previous plot, the following values are obtained:  
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To conclude, we chose a replacement volume of 2µL because it allowed to reach 99% 
of the cryoprotecting concentration in 22 steps (yielding a comfortable 27s in between 
volume exchanges considering the 10min evaporation limit) while setting the highest 
osmotic change undergone by the crystal to only 20% of the cryoprotecting 
concentration. 
 
